



OPSENS INC.

ANNUAL INFORMATION FORM

FOR THE FISCAL YEAR ENDED AUGUST 31, 2020

November 18, 2020

TABLE OF CONTENTS

| | | |
|-----|--|----|
| 1. | PRELIMINARY COMMENTS AND FORWARD-LOOKING STATEMENT | 4 |
| 2. | CORPORATE STRUCTURE | 4 |
| 2.1 | Name, Address, and Incorporation | 4 |
| 2.2 | Intercorporate Relationship | 5 |
| 3. | GENERAL DEVELOPMENT OF THE BUSINESS | 5 |
| 3.1 | Three-Year History | 6 |
| 4. | DESCRIPTION OF THE BUSINESS..... | 9 |
| 4.1 | General..... | 9 |
| A) | Summary | 9 |
| B) | Production and Services..... | 13 |
| C) | Specialized Skill and Knowledge | 14 |
| D) | Competitive Conditions | 14 |
| E) | New Products..... | 15 |
| F) | Components..... | 15 |
| G) | Intangible Properties | 16 |
| H) | Cycles | 17 |
| I) | Environmental Protection..... | 17 |
| J) | Employees..... | 17 |
| K) | Foreign Operations..... | 18 |
| L) | Lending | 18 |
| 4.2 | Risk Factors..... | 18 |
| 5. | DIVIDENDS AND DIVIDEND POLICY | 33 |
| 6. | GENERAL DESCRIPTION OF THE CAPITAL STRUCTURE..... | 33 |
| 6.1 | Common Shares | 33 |
| 6.2 | Stock Options Issued under the Corporation's Stock Option Plan | 33 |
| 7. | MARKET FOR SECURITIES | 34 |
| 7.1 | Market..... | 34 |
| 7.2 | Trading Price and Volume | 34 |
| 8. | ESCROWED SECURITIES | 35 |
| 9. | DIRECTORS AND OFFICERS..... | 35 |
| 9.1 | Name, Occupation and Securities Holding | 35 |
| 9.2 | Cease Trade Orders, Bankruptcies, Penalties or Sanctions..... | 40 |
| 10. | LEGAL PROCEEDINGS AND REGULATORY ACTIONS..... | 41 |

| | | |
|-------------|---|------------|
| 11. | AUDIT COMMITTEE | 42 |
| 11.1 | The Audit Committee’s Charter | 42 |
| 11.2 | Composition of the Audit Committee | 42 |
| 11.3 | Relevant Education and Experience | 42 |
| 11.4 | Audit Committee Oversight | 42 |
| 11.5 | Reliance on Certain Exemptions | 43 |
| 11.6 | Pre-Approval Policies and Procedures | 43 |
| 11.7 | External Auditor Service Fees | 43 |
| 12. | INTEREST OF MANAGEMENT AND OTHERS IN MATERIAL TRANSACTIONS | 43 |
| 13. | TRANSFER AGENT AND REGISTRAR | 43 |
| 14. | MATERIAL CONTRACTS | 44 |
| 15. | INTERESTS OF EXPERTS | 44 |
| 16. | ADDITIONAL INFORMATION | 44 |
| | SCHEDULE “A” | A-1 |

1. PRELIMINARY COMMENTS AND FORWARD-LOOKING STATEMENT

THE INFORMATION IN THIS ANNUAL INFORMATION FORM IS DATED AS AT AUGUST 31, 2020, UNLESS INDICATED OTHERWISE. ALL REFERENCES TO DOLLAR AMOUNTS IN THIS ANNUAL INFORMATION FORM ARE REFERENCES TO CANADIAN DOLLARS, UNLESS STATED OTHERWISE.

This Annual Information Form may contain or incorporate by reference forward-looking statements about the objectives and strategies of OpSens Inc. (the “Corporation”) as well as management’s expectations regarding its future growth, financial position and results of operations and the Corporation’s activities. These statements are forward-looking because they are based on assumptions about future economic conditions and courses of action that will be undertaken by the Corporation. These statements are subject to a number of risks and uncertainties, including, but not limited to the general economic conditions associated with the current outbreak of the novel coronavirus known as COVID-19 (please refer to section “Risk Factors”) which may cause actual results to differ materially from those contemplated by the forward-looking statements. The Corporation believes that the expectations reflected in these forward-looking statements are reasonable. However, there is no guarantee that the Corporation’s expectations in this regard will prove to be accurate and the reader must not unduly depend on them. The forward-looking statements are made on the date of this Annual Information Form. The Corporation is under no obligation to revise or update these forward-looking statements to reflect the events or circumstances that occur after the date of this Annual Information Form, except when it is required by law. There is no guarantee that the results, performance, or actual outcomes explicitly or implicitly expressed in these forward-looking statements will be achieved or, if they are achieved, will result in a profit.

The Corporation’s actual results may significantly differ from that indicated in the forward-looking statements resulting from the risk factors described in the section “Risk Factors” of this Annual Information Form.

2. CORPORATE STRUCTURE

2.1 Name, Address, and Incorporation

The Corporation was incorporated under the Part IA of the *Companies Act* (Québec) by articles of incorporation dated as of February 22, 2006 under the name “DCB Capital Inc.” and its French version “Capital DCB inc.”

In connection with its qualifying transaction pursuant to the TSX Venture Exchange (the “TSXV”) policies, the Corporation changed its name for “OpSens Inc.” on October 3, 2006 and amalgamated with 9174-3369 Québec Inc. on October 4, 2006.

The Corporation has been governed by the *Business Corporations Act* (Québec) (“QBCA”) since it replaced on February 14, 2011 the provisions of the *Companies Act* (Québec) relating to the incorporation and operation of business corporations.

In order to benefit from the provisions of section 153 of the QBCA, the Corporation amended its articles on February 6, 2012, in order to allow the directors of the Corporation to appoint one or more additional directors to hold office for a term expiring not later than the close of the next annual shareholders meeting, provided that the total number of directors so appointed may not exceed one third of the number of directors elected at the previous annual shareholders meeting.

On February 28, 2017, the Corporation received final approval of the listing of the Corporation's common shares on the Toronto Stock Exchange ("TSX"). The common shares commenced trading on the TSX on March 1, 2017, at market opening, under the symbol "OPS". In addition to listing on the TSX, the common shares were voluntarily delisted from the TSXV prior to the commencement of trading on March 1, 2017.

The Corporation's head and registered office is located at 750, boulevard du Parc-Technologique, Québec, Québec G1P 4S3.

2.2 Intercorporate Relationship

The Corporation beneficially owns 100% of votes attaching to all voting securities of OpSens Solutions Inc. ("OpSens Solutions") incorporated under the *Business Corporations Act* (Alberta).

In this Annual Information Form, unless otherwise indicated, "Corporation" means the Corporation and its subsidiary OpSens Solutions.

3. GENERAL DEVELOPMENT OF THE BUSINESS

The Corporation aims to become a key player in the physiological measurement market in cardiology with the OptoWire (the "OptoWire"), a nitinol-based optical guidewire. The OptoWire provides intra-coronary blood pressure measurements with unique, patented optical pressure guidewire technologies. It is immune to adverse effects related to blood contact and allows easy and reliable connectivity that leads to reliable measurements in extended conditions of usage. The OptoWire is also designed to provide cardiologists with a guidewire delivering optimized performances to navigate coronary arteries and cross blockages with ease and safety.

On November 5, 2019, the Corporation announced it was expanding its medical device business into the structural cardiology space and was accelerating development activities of products that reach beyond its current coronary and peripheral applications. This project has become the Corporation's largest research and development project.

The new area of focus of this expansion is aortic stenosis, a common and serious valve disease that is often treated through Trans Aortic Valve Replacement (TAVI). This is the fastest growing segment of cardiology, driven by an aging population and advancements in valve technology and technique that are bringing the procedure to a wider patient population.

The Corporation has recently been successfully working on this structural heart project and has sufficiently advanced the program to warrant further activities and investment to accelerate our time to market. The Corporation plans to build on its existing technology, infrastructure, and know-how in this complementary direction. Several positive development milestones have been announced since the news was released. More milestones are to be expected in the next four to six quarters on the way to a commercially viable product that can have an immediate impact on Trans Aortic Valve Replacement (TAVI) procedures.

In medical instrumentation, the Corporation also provides sensors to be integrated as critical components of products sold by established medical companies (i.e. Abiomed, Inc. (“Abiomed”)), as original equipment manufacturer (“OEM”).

The continued development of the OEM business segment is strategically important for the Corporation as it increases the critical mass in manufacturing, further advancing improvement initiatives. These agreements allow the Corporation to capitalize on the work done with long-time and newer partners. They also showcase the quality and benefits of its offer to the interventional cardiology market globally and demonstrate the accuracy of our measurement technology as well as the Corporation’s manufacturing capabilities.

The Corporation is also involved in industrial activities. The Corporation’s technology, expertise and products can serve several markets including aeronautics, geotechnical, infrastructures, nuclear, mining, military, and other markets. The inherent safety of the Corporation’s fiber-optic sensors allied with their robustness make them an attractive choice for those applications. The Corporation’s broad portfolio of products and technologies can be adapted to measure various parameters in the harshest conditions and provide significant advantages in terms of production optimization and reduced risk to the environment and health.

Since the Corporation’s reorganization of its corporate structure on September 1, 2015, the industrial activities of the Corporation have been consolidated in the OpSens Solutions business unit. As a result, only the medical activities have remained in the Corporation business unit.

3.1 Three-Year History

The events described below have influenced the general development of the business of the Corporation during the first months of the fiscal year ending August 31, 2021 and the last three fiscal years of the Corporation ended August 31, 2020, 2019 and 2018.

Beginning of Fiscal Year Ending August 31, 2021 and Up to the Date of this Annual Information Form

A detailed analysis of expected changes in the activities of the Corporation during fiscal year ended August 31, 2020 is presented in “Business Strategy” of the Management’s Discussion and Analysis for the fiscal year ended August 31, 2020 available on SEDAR at www.sedar.com and on the Corporation’s website at www.OpSens.com.

On October 14, 2020, the Corporation announced it had been awarded a 3-year contract by a major American Group Purchasing Organization (“GPO”). The contract provides access to the OptoWire to all their members across the United States.

Fiscal Year Ended August 31, 2020

On May 20, 2020, the Corporation announced that it had reached an important milestone with more than 100,000 patients evaluated with the OptoWire, its pressure guidewire for the diagnosis and treatment of coronary artery stenosis.

On March 24, 2020, the Corporation made an operational update in the context of the COVID-19 pandemic. Exempted from the province of Quebec's order to close non-essential businesses, the Corporation announced that it would continue to provide its cardiovascular diagnostic and treatment solutions to meet the needs of doctors and patients worldwide. The Corporation also described the precautions taken to maintain the health, well-being, and safety of its employees and to provide uninterrupted service to its customers.

On January 13, 2020, the Corporation announced it had received approval from the U.S. Food and Drug Administration ("FDA") to market its OptoWire III, the third generation of its guidewire for the diagnosis and treatment of cardiovascular disease (the "OptoWire III"). In addition to the United States and Canada, the Corporation has also filed applications for approval in Japan, and Europe.

On December 19, 2019, the Corporation announced it had received approval from the FDA to market its diastolic pressure algorithm ("dPR"). Consequently, the dPR has now been approved in Japan, Canada, Europe, and the United States.

Physiological measurement is constantly evolving following the increased use of Fractional Flow Reserve ("FFR"), the support of solid clinical data and the recommendations of cardiology societies. The option of physiological measurement without hyperemia induced by the injection of heart-stimulating drugs appeared and the Corporation developed its diastolic pressure algorithm to meet this need. Pressure indicators without hyperemia, such as the Corporation's dPR, are beneficial for some patients because they reduce time, cost, and discomfort during the procedure.

On November 7, 2019, the Corporation announced the world's first clinical use of the OptoWire III, following Health Canada approval. The OptoWire III is a guidewire integrating a second-generation optical sensor for vascular physiological measurement, such as FFR. This pressure guidewire is designed to offer the lowest drift in the industry and excellent access to lesions. Health Canada's approval paved the way for first use of the product by interventional cardiologist Olivier F. Bertrand, from the Quebec Heart and Lung Institute. In addition to Canada, the Corporation has also filed applications for approval in Japan, the United States and Europe.

On November 5, 2019, the Corporation announced its intention to expand its medical device business into the structural cardiology space and to accelerate development activities of products that reach beyond its current coronary and peripheral applications. The initial area of focus of this expansion is aortic valve stenosis.

Fiscal Year Ended August 31, 2019

On June 17, 2019, the Corporation announced that OpSens Solutions had partnered with Temai Ingenieros S.L. for the commissioning of an optical fuel monitoring system for a major aircraft manufacturer.

On April 30, 2019, the Corporation announced the signature of a supply agreement as part of its long-term collaboration with Abiomed for the Impella CP[®] heart pump. Abiomed awarded the Corporation a five-year contract to supply a critical portion of its heart pump technology. The agreement with mutual renewal clauses followed a co-development contract and a license to integrate the Corporation's miniature optical pressure sensor into the Impella CP[®] cardiac pumps signed in 2014.

On March 4, 2019, the Corporation announced the appointment of Mr. Alan Milinazzo as Executive Chairman of the Board of Directors. See section "Directors and Officers" of this Annual Information Form for a more detailed biography of Mr. Milinazzo. Mr. Denis M. Sirois remains on the Board of Directors of the Corporation.

On February 27, 2019, the Corporation announced the signing of an \$8 million credit agreement with CIBC Innovation Banking.

On January 9, 2019, the Corporation announced the receipt of CE Marking for its diastolic pressure algorithm dPR. The Corporation's dPR was designed to measure intracoronary pressure without the injection of stimulant drugs to diagnose coronary heart disease. The dPR will work in combination with the OptoWire and the OptoMonitor.

On November 27, 2018, the Corporation announced that it had obtained approval from Health Canada to commercialize its diastolic pressure algorithm dPR to measure intracoronary pressure to establish a diagnosis without the injection of stimulant drugs and to guide the diagnosis and treatment of patients with coronary heart disease.

On November 8, 2018, the Corporation announced that its diastolic pressure algorithm dPR, had been used for the first time by Dr. Hitoshi Matsuo, cardiologist, and President of the Gifu Heart Center Japan.

On November 1, 2018, the Corporation announced that it had reached an important milestone with more than 50,000 patients assessed with the OptoWire, a pressure guidewire used to measure FFR to diagnose and treat cardiovascular disease.

On September 20, 2018, the Corporation announced it had developed the dPR, a product that will allow the diagnosis of coronary heart blockages without the injection of stimulant drugs. This new product will be the Corporation's resting pressure measurement method. Filing for regulatory approvals had been completed in targeted territories. The Corporation planned to begin commercialization by the end of calendar year 2018. It will be available through the OptoMonitor and will work in combination with the OptoWire.

Fiscal Year Ended August 31, 2018

On April 24, 2018, the Corporation announced it was applauding the Japanese government's new requirement for the evaluation of any coronary stenosis prior to its treatment, specifically mentioning FFR as a preferred assessment method. The Japanese government revised medical fees and established requirements that functional ischemia (blockage of arteries) be evaluated before treatment for stable coronary artery disease. This new review regulation was consistent with the results of multiple studies, such as the FAME study, which demonstrated that, when a patient's lesion was assessed with FFR prior to treatment selection, clinical outcome was improved significantly. This new regulation was expected to have a positive impact on FFR penetration in the Japanese market, which then represented the largest user of the Corporation's FFR products.

On April 3, 2018, the Corporation announced that the integration of its technology, within the Impella Cardiac Pump®, marketed by its client Abiomed had been approved by the FDA. This news followed the US\$6 million cooperation and development agreement signed in April 2014 (the "License Agreement"). As part of this License Agreement, the Corporation granted Abiomed an exclusive worldwide license to include its miniature pressure sensor in circulatory assist devices. This approval released a new milestone payment of US\$500,000 to the Corporation. The granting of this license to Abiomed was part of the Corporation's strategy to capitalize on the development of its sensor by offering select partners the rights to exploit sensors in specific areas while focusing on the Corporation's products for FFR. See section "License" of this Annual Information Form for more details about the License Agreement.

On January 23, 2018, the Corporation announced that Claude Belleville, Vice-President, Medical was retiring, but will continue as consultant for the Corporation to ease the transition.

On November 27, 2017, the Corporation announced the full conversion in common shares of the US\$2 million debenture held by Zeon Medical Inc., the Corporation's Japanese partner, which was granted the exclusive distribution rights in Japan, Korea and Taiwan in 2012 for the Corporation's products designed to measure FFR.

4. DESCRIPTION OF THE BUSINESS

4.1 General

The Corporation primarily focuses on physiological measurement in the diagnosis and treatment of coronary stenosis. The Corporation offers an advanced optical-based pressure guidewire, the OptoWire, which aims at improving the clinical outcome of patients with coronary artery disease. The Corporation is also involved in industrial activities. The Corporation develops, manufactures and installs innovative fibre optic sensing solutions for critical applications in industrial applications.

A) Summary

To strengthen its medical identity to develop its full potential in the physiological measurement market, the Corporation reorganized, on September 1, 2015, its corporate structure. Following the reorganization, the Corporation is now organized into two segments: Medical and Industrial.

- *Medical* – In this segment, the Corporation focuses mainly on physiological measurement in interventional cardiology (the “Medical Segment”).
- *Industrial* – In this segment, the Corporation develops, manufactures and installs innovative fiber optic sensing solutions for critical applications such as the monitoring of composite reservoir structures in the aeronautic industry, temperature in the semi-conductor manufacturing equipment, and other demanding industrial applications (the “Industrial Segment”).

The principal factors employed in the identification of the two segments reflected in this note include the Corporation’s organizational structure, the nature of the reporting lines to the President and Chief Executive Officer and the structure of internal reporting documentation such as management’s accounts and budgets.

Sales between segments are carried out at cost plus a reasonable margin.

The following table shows the revenues and the percentage for each reportable segments of the Corporation for the fiscal years ended August 31, 2020 and 2019.

| Sales to Third Parties | Fiscal Years Ended August 31 | | | |
|------------------------|------------------------------|--------------|--------------|-------------|
| | 2020 (\$) | 2020 (%) | 2019 (\$) | 2019 (%) |
| Medical Segment | 26,996,184 | 91.7 | 30,334,061 | 92.6 |
| Industrial Segment | 2,457,166 | 8.3 | 2,417,457 | 7.4 |
| Total | 29,453,350 | 100.0 | 32,751,518 | 100.0 |

Medical Segment

Under this reportable segment, the Corporation has integrated its miniature fiber optic pressure sensor into an innovative guidewire designed to navigate through the vascular system to reach lesions with ease. The technical advantages of the Corporation’s products to measure physiology are likely to enable it to take a share of the market.

According to management and industry sources’ estimate, the global FFR market exceeded US\$500 million in 2020 and should exceed US\$1 billion annually in the medium term (2025)¹. Physiological measurement is recognized as the standard in the diagnosis of the severity of coronary lesions, which leads to better outcomes for patients.

¹ The Corporation’s FFR Market Calculations based on GRAND VIEW RESEARCH (February 2019).

In cardiology, physiological measurement, performed by FFR or dPR, is an index of the functional gravity of coronary stenoses. It is calculated from pressure measurements taken before and after a narrowing of the arteries during coronary angiography. This approach provides an immediate diagnostic that allows a better assessment of the suitability of the installation of a stent to improve blood circulation in the cardiovascular system.

For the marketing of its products to measure FFR, the Corporation anticipates the establishment of partnerships with distributors in every major geographic area. A distribution agreement covering Japan, Korea and Taiwan was signed on November 19, 2012 with a Japanese-based medical corporation (the “Distribution Agreement”) in a US\$5 million transaction. Under the terms of the Distribution Agreement, conditions are as follows:

- US\$3 million for the distribution rights for the Corporation’s FFR products for Japan, Korea, and Taiwan, which includes:
 - US\$2 million at signing;
 - US\$1 million upon receipt of regulatory approval for the Corporation’s FFR products in Japan, which was obtained on October 2, 2014;
- US\$2 million in convertible debenture at signing.

The Corporation has signed distribution agreements for many countries in Europe and in the Middle East. Additional distribution agreements are being negotiated and should be finalized in 2021 and beyond.

As part of its continuous improvement process, the Corporation is expanding its medical device business into the structural cardiology space and is accelerating the development activities of products that reach beyond its current coronary and peripheral applications. It has become the largest research and development project for the Corporation.

The initial area of focus of this expansion is aortic stenosis, a common and serious valve disease that is often treated through Trans Aortic Valve Replacement (TAVI). This is the fastest growing part of structural cardiology, driven by an aging population and advancements in valve technology and technique that are bringing the procedure to a wider patient population.

The Corporation has recently been successfully working on this structural cardiology project and has sufficiently advanced the program to warrant further activities and investment to accelerate our time to market. The Corporation plans to build on its existing technology, infrastructure, and know-how in this complementary direction. Several positive development milestones are to be expected in the next four to six quarters on the way to a commercially viable product that can have an immediate impact on TAVI procedures.

The Corporation will also continue to develop the OptoWire and OptoMonitor to provide cardiologists with the most effective tools. The development of new versions of the OptoWire and OptoMonitor for physiological measurement remains an important project. During fiscal year ended August 31, 2020, the Corporation received approval from regulatory authorities in Canada, Japan and the United States for the OptoWire III, and from Canada, the United States, Japan, and the Europe for the OptoMonitor III.

During fiscal year ended August 31, 2019, the Corporation developed the dPR, a product for the diagnosis of coronary blockages without the injection of stimulating drugs. The dPR is the Corporation's resting pressure measurement method. It is available via the OptoMonitor and works in combination with the OptoWire. The dPR is marketed in Japan, the United States, Canada, and Europe.

Industrial Segment

Under this reportable segment, the Corporation's technology, expertise, and products can serve several markets including aeronautic, geotechnical, infrastructures, nuclear, mining, military, and others.

Nuclear market – The opportunities in this market are related principally to new nuclear technologies for producing energy. The new and recently patented fiber optic differential pressure sensor is the main product for these applications.

Aeronautics market – The opportunities in this market are principally related to fuel monitoring systems for aircraft. The new industrial version of the absolute pressure sensor and the recent addition of a differential pressure sensor are the main products for these applications.

Traditional Niche Applications Market – They include niche applications in which the Corporation is currently engaged, such as electro-pyrotechnic devices.

Pressure Monitoring Solution Market – The opportunities in this market are principally related to absolute and differential pressure measurements. The measurement of pressure is found in many industrial applications in the energy, geotechnical, oil and gas and aeronautic sectors. New industrial versions of the pressure sensor and the recent addition of a differential pressure sensor are the main flagship products for these applications.

New products such as the current pulse generator and the nuclear version of the Corporation's fiber optic sensor portfolio, introduced to the market for this reportable segment, will help the Corporation to maintain its leadership position in this area. All research and development efforts are conducted by the Corporation's employees.

B) Production and Services

Medical Segment

Under this reportable segment, the Corporation devotes extensive efforts to its physiological measurement activities. In this area, the Corporation develops, manufactures, and markets a comprehensive medical product that is sold through a network of distributors and a direct sales force. Developed by the Corporation, the OptoWire is the first patented nitinol-based optical guidewire for physiological measurement. The OptoWire provides intra-coronary blood pressure measurements with unique, patented optical pressure guidewire technologies. It is immune to adverse effects related to blood contact and allows easy and reliable connectivity that leads to reliable measurements in extended conditions of usage. The OptoWire is also designed to provide cardiologists with a guidewire that provides optimal performance to navigate coronary arteries and cross blockages with ease and safety. Paired with its guidewire, the Corporation has developed the OptoMonitor. The OptoWire and OptoMonitor combination allows its users to consolidate patient information on their hemodynamic system, which is also offered by competitors' products.

Physiological measurement provides an index calculated from the pressure measurements taken before and after the narrowing of arteries during a coronarography. The Corporation has developed the OptoWire for physiological measurement. This second-generation fiber optic pressure guidewire is designed to provide the lowest drift in the industry and excellent lesions access. Initially, the OptoWire measured only FFR, a physiological measurement taken while the patient receives the injection of stimulant drugs.

Last year, the Corporation launched the dPR, a product providing physiological measurement allowing the diagnosis of coronary blockages without the injection of stimulant drugs. This is the Corporation's resting pressure measurement method.

Sensors for medical instrumentation measure temperature and pressure. The main features of these sensors are size, strength and the absence of drift during operation. In medical instrumentation, the Corporation markets products as original equipment manufacturer or directly to end-users. These products are in the commercial phase.

Industrial Segment

Fiber optic sensors perform well in the presence of electromagnetic fields, radiofrequencies, micro-waves, high-intensity magnetic waves (MR) or high temperatures, elements that typically disrupt results with conventional sensors.

In the industrial sector, customers' needs are wide-ranging and require measuring various parameters like pressure, temperature, strain, and others. The Corporation is focusing on business opportunities with highest returns and has developed new products to fulfill their specific needs. Amongst others, the new OPP-GD fiber optic differential pressure sensor and the OEC fiber optic extensometer sensors have grabbed the attention of many industries such as aeronautic and energy.

C) Specialized Skill and Knowledge

Medical Segment

Under this reportable segment, the Corporation has a research and development department that includes engineering, testing, and prototyping. This department employs 15 people who work, on a permanent basis, to improve existing products and do research and development for new products. These employees are engineers and optical and software technicians.

Industrial Segment

Under this reportable segment, the Corporation has a research and development department that includes engineering, testing, and prototyping. This department employs eight people who work, on a permanent basis, to improve existing products and do research and development for new products. These employees are engineers and optical and software technicians.

D) Competitive Conditions

The competitive conditions vary depending on the markets where the Corporation's sensors are used. In general, the products offered by the Corporation have an added value compared with conventional and optical systems typically used in various conditions. The Corporation makes sure it highlights this added value when addressing its target markets.

Medical Segment

In the physiological measurement market, four corporations offer products to measure FFR and dPR (or their equivalent version). These corporations are Abbott, Philips, Boston Scientific Corporation and ACIST. Both Abbott and Philips use electrical sensors in their guidewire to get the blood pressure measurement. ACIST uses fiber optic sensors combined with a microcatheter used over a standard guidewire. The Corporation and Boston Scientific Corporation use optical sensors in their guidewire to get blood pressure measurement. The Corporation's guidewire is instrumented with a pressure sensor. It is different on several aspects, from accuracy and reliability of the sensing technology, mechanical performances, and connectivity of the guidewire. Optical sensing technology aims to provide reliable measurement in the human body. The main geographic markets where the competitive companies are selling their products for physiological measurement are the United States, Canada, Europe, and Japan.

Industrial Segment

The Corporation's industrial line of fiber optic sensors offers unique advantages over traditional sensors in many industries. For example, traditional sensors need to be shielded and grounded for their safe operation in aircrafts and spaceships. The use of composite materials in the newly developed versions of these flying structures have seriously reduced the natural shielding and grounding capacity provided by the older metallic version of these structures. The Corporation's fiber optic strain and pressure sensors received attention from major players in the aeronautic industry because they do not require any shielding or grounding and because of their ease of deployment. In the Industrial Segment, several companies manufacture conventional and optical sensors to measure strain, temperature, pressure, and other parameters. Competition comes from local corporations as well as international corporations.

E) New Products

Medical Segment

To complement and enhance its offering, the Corporation is constantly developing and offering new products or instruments that complement or improve existing products and instruments. For this reportable segment, the new products to be marketed are the OptoWire III and the OptoMonitor III.

As of the date of this Annual Information Form, the Corporation received approval to commercialize its physiological measurement products in the United States, Europe, Japan, and Canada.

The Corporation is currently expanding its medical device business into the structural cardiology space. The new area of focus is aortic stenosis, a common and serious valve disease that is often treated through TAVI. This is the fastest growing segment of cardiology. It is driven by an aging population and advancements in valve technology and technique that are bringing the procedure to a wider patient population.

Now that its products for cardiology have taken their place in the market, the Corporation has been working on this structural cardiology project, building on its existing technology to develop a pressure guidewire that aims to optimize the implantation of replacement aortic valves. This new guidewire will provide continuous hemodynamic pressure measurements before, during and after the procedure. The guidewire will also simplify the work of cardiologists by minimizing the number of steps and the exchange of equipment to promote safety and speed of intervention. The product is planned to reach the market in 2022.

Industrial Segment

The Corporation is continuously maintaining its line of products and solutions at the cutting edge of technology to meet the customers' most challenging needs. New products such as the current pulse generator and the version for the nuclear market of the Corporation's fiber optic sensor portfolio, introduced to the market for this reportable segment, will help the Corporation to maintain its leadership position in this area.

F) Components

Raw material used by the Corporation is mostly electronic and optical parts. The Corporation's supply policy allows access to more than one supplier for a large proportion of its needs. The Corporation has never had significant supply problems in the past and does not foresee supply problems in the near future for any of its reportable segments. Delivery of electronic parts and of a few optical components may occasionally be delayed. To overcome this problem, the Corporation maintains a minimum inventory level for the most strategic parts and components and is also always looking for alternative suppliers for both of its reportable segments. The Corporation does not expect unusual price increases for its raw material in the coming quarters, for both of its reportable segments. For its products for physiological measurement, the Corporation signed supply agreements with key suppliers to minimize the risk of supply interruption.

G) Intangible Properties

i) Patents

Considering the time and investment required to develop new products, the Corporation's first strategic move is to protect its intellectual property. To allow the Corporation to serve its markets, to benefit from freedom of operation and to protect its innovations, it holds, as of the date of this Annual Information Form, ten patents and filed nine patent applications covering geographical areas such as Canada, the United States, Europe, Japan and China. The Corporation's patents expire at various dates through 2036. The Corporation intends to continue to expand its intellectual property position to protect the design and use of its products.

ii) Trademark

The Corporation is the holder of the  trademark registered in Canada since May 16, 2006. Such registration will expire on May 16, 2021.

The Corporation is the holder of the OptoWire trademark registered in Japan and the United States and it will expire in 2024 and 2026, respectively. This trademark is registered in Canada since July 13, 2017 and will expire on July 11, 2032.

The Corporation is the holder of the OptoMonitor trademark registered in Japan and the United States and it will expire in 2024 and 2026, respectively. This trademark is registered in Canada since July 11, 2017 and will expire on July 11, 2032.

The Corporation is the holder of the Fidela trademark registered in the European Union that will expire on March 2, 2030. Registration is pending in the United States.

iii) License

On April 15, 2014, the Corporation announced it had entered into the License Agreement with Abiomed in connection with its miniature optical pressure sensor technology for applications in circulatory assist devices. The Corporation has granted Abiomed an exclusive worldwide license to integrate its miniature optical pressure sensor in connection with Abiomed's circulatory assist devices. Under the License Agreement, Abiomed paid the Corporation an aggregate amount of US\$6 million. Of that amount, US\$1.5 million was paid upon closing, while the balance has been disbursed based on the achievement of certain milestones, such as the meeting of certain performance requirements, the filing of a regulatory application, the obtaining of a regulatory approval and the transfer of manufacturing to Abiomed.

On August 16, 2010, the Corporation reached an agreement to license its technology in the high-power transformers business to a subsidiary of LumaSense Technologies Inc. of Santa Clara, California, representing the Corporation's exit from that line of business. Such agreement gives exclusive and perpetual rights to use the Corporation's technology in the transformer business.

iv) Supply Contract

On April 30, 2019, the Corporation announced a supply agreement as part of its long-term collaboration with Abiomed for the Impella CP® heart pump.

Abiomed awarded the Corporation a five-year contract to supply a critical portion of its heart pump technology. The agreement, with mutual renewal clauses, follows a co-development contract and a license to integrate the Corporation's miniature optical pressure sensor into the Impella CP® cardiac pumps signed in 2014.

H) Cycles

For the Medical Segment, activities are generally slower in the fourth quarter due to the summer vacations of physicians. For the Industrial Segment, activities are generally higher in fall and winter quarters.

In the third and the fourth quarters of fiscal year ended August 31, 2020, activities were slower due to the COVID-19 pandemic.

I) Environmental Protection

The Corporation is subject to various federal, provincial, and local environmental and occupational health and safety laws and regulations in Canada where operations in both of its reportable segments are conducted. Such laws and regulations concern notably wastewater, storm water flows and disposal of solid waste. Production facilities occasionally produce small quantities of hazardous waste that is recycled or transferred off site in accordance with the applicable regulations.

The Corporation complies in all material aspects with Canadian environmental requirements. Investment in capital property and other expenditures are made and incurred in a timely manner to maintain said compliance. These investments made with regards to environmental protection have had no operational or financial impact on the expenses in capital property, profit or loss or on the competitive position in both reportable segments of the Corporation during the fiscal year ended August 31, 2020.

J) Employees

As of August 31, 2020, the Corporation counted 161 employees in both reportable segments. Of this number, 144 employees, working for the Medical Segment, are in Canada, Europe, and the United States. All 17 employees working for the Industrial Segment are in Canada.

The Corporation's group of employees is composed of a multidisciplinary team grouping scientific and technical expertise in various fields such as software development, electronics, optics, physics, chemistry, civil engineering, mechanical engineering and geomechanical engineering. The Corporation provides its employees with an environment that is favourable to sustained development of their skills and full achievement of their ambitions. Training and development of the employees are key elements in the Corporation's growth.

Employees of both reportable segments of the Corporation are not unionized. Working conditions, that are periodically revised, are governed by written agreement between on the one hand any reportable segments of the Corporation and on the other hand their respective employees.

K) Foreign Operations

The proportion of export revenues in consolidated sales should be assessed in relation to business growth in the medical field, especially in physiological measurement.

The following table presents the Corporation's consolidated revenues in both reportable segments by geographic sector for the fiscal years ended August 31, 2020 and 2019.

| Revenues per Geographic Sector ⁽¹⁾ | Fiscal Years Ended August 31 | |
|---|------------------------------|--------------|
| | 2020 (\$) | 2019 (\$) |
| United States | 11,408,452 | 14,016,549 |
| Japan | 6,313,784 | 10,068,564 |
| Canada | 2,644,881 | 2,744,248 |
| Other ⁽²⁾ | 9,086,233 | 5,922,157 |
| Total | 29,453,350 | 32,751,518 |

Notes:

- (1) Revenues are attributed to the geographic sector based on the clients' location.
- (2) Comprised of revenues generated in countries for which amounts are individually not significant.

L) Lending

The investment policy is approved by the Board of Directors and it is primarily focused on the protection of capital while considering the performance and fiscal aspects. The Corporation carries out investment transactions with recognized financial institutions with credit ratings of at least A and higher, in either bonds, money market funds or guaranteed investment certificates.

4.2 Risk Factors

The Corporation operates in industries that contain various risks and uncertainties. The risks and uncertainties listed below are not the only ones to which the Corporation is subject. Additional risks and uncertainties not presently known by the Corporation, or which the Corporation deems to be currently insignificant, may impede the Corporation's performance. The materialization of one of the following risks could harm the Corporation's activities and have significant negative impacts on its financial situation and its operating results. In that case, the Corporation's stock price could be affected.

The global economy has, at various times in the past and may in the future, experience extreme volatility in response to economic shocks or other events, such as the recent outbreak of respiratory illness caused by the novel coronavirus ("COVID-19"). The global economy has significantly changed during the past few months. The spread of COVID-19, declared on March 11, 2020 as a pandemic by the World Health Organization (WHO), has led many governments to adopt exceptional measures to slow the advancement of COVID-19.

Many industries, including the medical industry, are impacted by volatile market conditions in response to the widespread outbreak of epidemics, pandemics, or other health crises. Some of the key impacts of these conditions include devaluations and high volatility in global equity, commodity, foreign exchange and medical and industrial markets and a lack of market confidence and liquidity. Financial institutions and large corporations may be forced into bankruptcy or need to be rescued by government authorities. Access to financing may also be negatively impacted by future liquidity crises throughout the world. These factors may impact the Corporation's ability to obtain equity or debt financing and, where available, to obtain such financing on terms favorable to the Corporation. Increased levels of volatility and market turmoil could have a material adverse impact on the Corporation's operations and planned growth and the trading price of the securities of the Corporation may be adversely affected.

In addition, the international response to the spread of COVID-19 has led to significant restrictions on travel, temporary business closures, quarantines, and a general reduction in consumer activity. In addition, the increasing number of individuals infected with COVID-19 could result in a widespread global health crisis that could adversely affect global economies and financial markets. In particular, the continued spread of COVID-19 globally could materially and adversely impact the Corporation's business, including without limitation, employee health, workforce availability and productivity, limitations on travel, supply chain disruptions, increased insurance premiums, the availability of industry experts and personnel and other factors that depend on future developments beyond the Corporation's control.

Even though the Corporation is implementing business continuity measures to mitigate and reduce any potential impacts of COVID-19 on its business, operations, supply chain and financial condition, the spread of COVID-19 could have a material adverse impact on the Corporation's workforce and the development of its projects. These events cause significant uncertainties that could damage the Corporation's activities.

The full extent and impact of COVID-19 on the Corporation's operations cannot currently be ascertained, as it depends upon future developments which cannot be predicted, and includes among other matters: the duration of the outbreak, the severity of the virus and the ability to treat it, the ability to collect sufficient data to track the virus and the collective actions taken to curb the spread of the virus. At the current time, it is not possible to reliably estimate the duration and impact of these events may have on the Corporation's future financial results because of the uncertainties about future developments. However, thus far, the Corporation has had no manufacturing, supply chain, or distribution disruptions and has continued to fulfill orders to customers.

In the physiological measurement market, the Corporation is dependent on the success of the OptoWire, its guidewire measuring FFR and dPR, and cannot be certain that it will achieve the broad acceptance necessary to develop a profitable business. Expected future revenues are primarily derived from sales of the OptoWire. The OptoWire is designed to provide cardiologists with a pressure guidewire to navigate coronary arteries and cross blockages with ease, while also measuring intra-coronary blood pressure. The Corporation expects that sales of its physiological measurement products will account for a majority of its revenues for the foreseeable future; however it is difficult to predict the penetration and future growth rate or size of the market for physiological measurement technology. The expansion of the physiological measurement market depends on several factors, such as:

- physicians accepting the benefits of the use of physiological measurement products in conjunction with angiography;
- physician experience with physiological measurement products either used alone or jointly used in a single percutaneous coronary intervention, or PCI;
- the availability of training necessary for proficient use of physiological measurement products, as well as willingness by physicians to participate in such training;
- the additional procedure time required for use of physiological measurement products compared to the perceived benefits;
- the perceived risks generally associated with the use of the physiological measurement products and procedures, especially its new products and procedures;
- the placement of the physiological measurement products in treatment guidelines published by leading medical organizations;
- the availability of alternative treatments or procedures that are perceived to be or are more effective, safer, easier to use or less costly;
- hospitals' willingness, and having sufficient budgets, to purchase physiological measurement products;
- the size and growth rate of the PCI market in the major geographies in which the Corporation operates;
- the availability of adequate reimbursement; and
- the success of the Corporation's marketing efforts and publicity regarding physiological measurement technology.

Even if physiological measurement technology gains wide market acceptance, these products may not adequately address market requirements and may not continue to gain market acceptance among physicians, healthcare payors and the medical community due to factors such as:

- the lack of perceived benefit from information related to pressure characteristics of blood around blockages available to the physician;
- the actual and perceived ease of use of the physiological measurement products;
- the quality of the measurements provided by the physiological measurement products;
- the cost, performance, benefits, and reliability of the physiological measurement products relative to competing products and services; and
- the extent and timing of technological advances.

If physiological measurement technology generally, or the physiological measurement products specifically designed to measure FFR and dPR, do not gain wide market acceptance, the Corporation may not be able to achieve its anticipated growth, revenues or profitability and its results of operations would suffer.

The risks inherent in the Corporation's international operations may adversely impact its revenues, results of operations and financial condition. The Corporation anticipates that it will derive a significant portion of its revenues from operations in Japan, the United States and Europe. As the Corporation expands internationally, it will need to retain and train its distributors, hire, train and retain qualified personnel for its direct sales efforts and train other personnel in countries where language, cultural or regulatory impediments may exist. The Corporation cannot ensure that distributors, physicians, regulators, or other government agencies outside Canada will accept its products, services, and business practices. Current or future trade, social and environmental regulations or political issues could restrict the supply of resources used in production or increase its costs. Compliance with such regulations is costly. Any failure to comply with applicable legal and regulatory obligations could impact the Corporation in a variety of ways that include, but are not limited to, significant criminal, civil and administrative penalties, including imprisonment of individuals, fines and penalties, denial of export privileges, seizure of shipments and restrictions on certain business activities. Failure to comply with applicable legal and regulatory obligations could result in the disruption of the Corporation's manufacturing, shipping, and sales activities. The Corporation's international sales operations expose it and its representatives, agents, and distributors to risks inherent in operating in foreign jurisdictions, including:

- the Corporation's ability to obtain, and the costs associated with obtaining export licenses and other required export or import licenses or approvals;
- changes in duties and tariffs, taxes, trade restrictions, license obligations and other non-tariff barriers to trade;
- burdens of complying with a wide variety of foreign laws and regulations related to healthcare products;
- costs of localizing product and service offerings for foreign markets;
- business practices favoring local companies;
- longer payment cycles and difficulties collecting receivables through foreign legal systems;
- difficulties in enforcing or defending agreements and intellectual property rights;
- differing local product preferences, including because of differing reimbursement practices;
- fluctuations in foreign currency exchange rates and their impact on the Corporation's operating results; and
- changes in foreign political or economic conditions in response to, among other things, the COVID-19 pandemic.

The Corporation cannot ensure that one or more of these factors will not harm the Corporation. Inability to expand the Corporation's international operations would adversely impact its revenues, results of operations and financial condition.

If the third-party distributors that the Corporation will rely on to market and sell its products are not successful, the Corporation may be unable to increase or maintain its level of revenues. A portion of its revenue will be generated by third-party distributors, especially in international markets. If these distributors cease or limit operations or experience a disruption of their business operations, or are not successful in selling the Corporation's products, it may be unable to increase or maintain its level of revenues, and any such developments could negatively affect its international sales strategy. Over the long term, the Corporation intends to grow its business internationally, and to do so it will need to attract additional distributors to expand the territories in which the Corporation does not directly sell its products. The Corporation's distributors may not commit the necessary resources to market and sell its products. If current or future distributors do not continue to distribute the Corporation's products or do not perform adequately or if the Corporation is unable to locate distributors in particular geographic areas, it may not realize revenue growth internationally.

The Corporation may require significant additional capital to pursue its growth strategy, and its failure to raise capital when needed could prevent the Corporation from executing its growth strategy. The Corporation believes that its existing cash and cash equivalents will be sufficient to meet its anticipated cash needs for at least the next 12 months. However, the Corporation may need to obtain additional financing to pursue its strategy, to respond to new competitive pressures or to act on opportunities to acquire or invest in complementary businesses, products, or technologies. The timing and amount of the Corporation's working capital and capital expenditure requirements may vary significantly depending on numerous factors, including:

- market acceptance of its products;
- the revenues generated by its products;
- the development of new products, including products that reach beyond the Corporation's current coronary and peripheral applications;
- the need to adapt to changing technologies and technical requirements, and the costs related thereto;
- the costs associated with expanding its manufacturing, marketing, sales, and distribution efforts;
- the existence and timing of opportunities for expansion, including acquisitions and strategic transactions;
- the impacts of the COVID-19 pandemic; and
- costs and fees associated with defending existing or potential litigation.

The Corporation faces intense competition and may not be able to keep pace with the rapid technological changes in the medical devices industry. The medical device market is intensely competitive and is characterized by extensive research and development and rapid technological change. The Corporation's future customers will consider many factors when choosing suppliers, including product reliability, clinical outcomes, product availability, inventory consignment, price and product services provided by the manufacturer, and market share can shift as a result of technological innovation and other business factors. Major shifts in industry market share have occurred in connection with product problems, physician advisories and safety alerts, reflecting the importance of product quality in the medical device industry, and any quality problems with the Corporation's processes, goods and services could harm its reputation for producing high-quality products and erode its competitive advantage, sales and potential market share.

The Corporation's competitors are larger companies which have significantly greater resources and broader product offerings than the Corporation, and it anticipates that in the coming years, other technologies or corporations could enter the physiological measurement market. One of these risks is the change in the way coronary physiology data are obtained. In addition, the Corporation expects that competition will intensify with the increased use of strategies such as consigned inventory, preferential pricing and bundling of products, and the Corporation anticipates increasing price competition as a result of managed care, consolidation among healthcare providers, increased competition and declining reimbursement rates. Product introductions or enhancements by competitors which have advanced technology, better features or lower pricing may make the Corporation's products or proposed products obsolete or less competitive. As a result, the Corporation will be required to devote continued efforts and financial resources to bring its products under development to market, enhance its existing products and develop new products for the medical marketplace. If the Corporation fails to develop new products, enhance existing products, or compete effectively, the Corporation's financial condition and results of operations will be adversely affected.

If the Corporation fails to properly manage its anticipated growth, the Corporation could suffer. Rapid growth of the Corporation is likely to place a significant strain on its managerial, operational, and financial resources and systems. To execute the Corporation's anticipated growth successfully, it must attract and retain qualified personnel and manage and train them effectively. The Corporation anticipates hiring additional distributors and personnel to assist in the commercialization of its current products and in the development of future products. The Corporation will be dependent on its personnel and third parties to effectively market and sell its products to an increasing number of customers. It will also depend on its personnel to develop and manufacture in anticipated increased volumes its existing products, as well as new products and product enhancements. Further, the Corporation anticipated growth will place additional strain on its suppliers resulting in increased need for it to carefully monitor for quality assurance. Any failure by the Corporation to manage its growth effectively could have an adverse effect on its ability to achieve its development and commercialization goals.

If the Corporation is unable to protect its intellectual property effectively, its financial condition and results of operations could be adversely affected. Patents and other proprietary rights are essential to the Corporation and its ability to compete effectively with other companies is dependent upon the proprietary nature of its technologies. The Corporation also relies upon trade secrets, know-how, continuing technological innovations and licensing opportunities to develop, maintain and strengthen its competitive position. The Corporation seeks to protect these, in part, through confidentiality agreements with certain employees, consultants and other parties. The Corporation pursues a policy of generally obtaining patent protection in both Canada and in key foreign countries for patentable subject matter in its proprietary devices and also attempt to review third-party patents and patent applications to the extent publicly available to develop an effective patent strategy, avoid infringement of third-party patents, and monitor the patent claims of others.

The Corporation currently owns numerous Canadian and foreign patents and has patent applications pending. The Corporation cannot be certain that any pending or future patent applications will result in issued patents, that any current or future patents issued will not be challenged, invalidated or circumvented or that the rights granted thereunder will provide a competitive advantage to it or prevent competitors from entering markets which the Corporation currently serves. In addition, the Corporation may have to take legal action in the future to protect its trade secrets or know-how or to defend itself against claimed infringement of the rights of others. Any legal action of that type could be costly and time consuming to the Corporation despite insurance policies owned by the Corporation and it cannot be certain of the outcome. The invalidation of key patents or proprietary rights which the Corporation owns or an unsuccessful outcome in lawsuits to protect its intellectual property could have a material adverse effect on its financial condition and results of operations.

Future patent litigation could be costly and disruptive to the Corporation and may have an adverse effect on its financial condition and results of operations. The Corporation operates in an industry that is susceptible to significant patent litigation and, in recent years, it has been common for companies in the medical device field to aggressively challenge the rights of other companies to prevent the marketing of new devices. Companies that obtain patents for products or processes that are necessary for or are useful to the development of its products may bring legal actions against the corporation claiming infringement. Defending intellectual property litigation is expensive and complex and outcomes are difficult to predict. Any pending or future patent litigation may result in significant royalty or other payments or injunctions that can prevent the sale of products and may cause a significant diversion of the efforts of the Corporation's technical and management personnel. While the Corporation intends to defend any such lawsuits vigorously, it cannot be certain that it will be successful. In the event that the Corporation's right to market any of its products is successfully challenged or if the Corporation fails to obtain a required license or is unable to design around a patent, the Corporation's financial condition and results of operations could be materially adversely affected.

Quality problems with the processes and products could harm the Corporation's reputation for producing high-quality products and diminish its competitive advantage, sales, and market share. The manufacturing of physiological measurement products is a highly rigorous and complex process, due in part to strict regulatory requirements. Any failure to manufacture physiological measurement products in accordance with product specifications could result in increased costs, lost revenues, field corrective actions, customer dissatisfaction or voluntary product recalls, any of which could harm the Corporation's profitability and commercial reputation. Problems may arise during manufacturing for a variety of reasons, including equipment malfunction, failure to follow specific protocols and procedures and problems with raw materials. Quality is extremely important to the

Corporation and its customers due to the serious and costly consequences of product failure. The Corporation's quality certifications are critical to the marketing success of its products. If the Corporation fails to meet these standards, its reputation could be damaged, it could lose customers, and its revenue and results of operations could decline. Aside from specific customer standards, the success of the Corporation depends generally on the ability to manufacture, to exact tolerances, precision-engineered components, subassemblies, and finished devices from multiple materials. If the components fail to meet these standards or fail to adapt to evolving standards, the Corporation's reputation as a manufacturer of high-quality devices will be harmed, its competitive advantage could be damaged, and it could lose customers and market share.

The loss of any of the Corporation's sole-source suppliers or an increase in the price of inventory supplied to it could have an adverse effect on the Corporation's financial condition and results of operations. The Corporation purchases certain supplies used in its manufacturing processes from single sources due to quality considerations, costs or constraints resulting from regulatory requirements. Agreements with certain suppliers are terminable by either party upon short notice and the Corporation has been advised periodically by some suppliers that in an effort to reduce their potential product liability exposure, they may terminate sales of products to customers that manufacture implantable medical devices, and the Corporation may not be able to establish additional or replacement suppliers for certain components or materials quickly. In addition, the Corporation may lose a sole-source supplier due to, among other things, the acquisition of such a supplier by a competitor (which may cause the supplier to stop selling its products to it), the bankruptcy of such a supplier or the impacts of the COVID-19 pandemic, which may cause the supplier to cease operations. A reduction or interruption by a sole-source supplier of the supply of materials or key components used in the manufacturing of the Corporation's products or an increase in the price of those materials or components could adversely affect the Corporation's financial condition and results of operations.

Instability in international markets or foreign currency fluctuations could adversely affect the Corporation's results of operations. Physiological measurement products will be marketed in many countries, with its largest geographic markets being Japan, Europe, and the United States. As a result, the Corporation faces currency and other risks associated with its international sales. The Corporation is exposed to foreign currency exchange rate fluctuations due to transactions denominated primarily in United States dollars and Euros, which may potentially reduce the Canadian dollars the Corporation receives for sales denominated in any of these foreign currencies and/or increase the Canadian dollars the Corporation reports as expenses in these currencies, thereby affecting its reported consolidated revenues, profit margins and results of operations. Fluctuations between the currencies in which the Corporation does business will cause foreign currency transaction gains and losses. The Corporation cannot predict the effects of currency exchange rate fluctuations upon its future operating results because of the number of currencies involved, the variability of currency exposures and the volatility of currency exchange rates.

In addition to foreign currency exchange rate fluctuations, there are a number of additional risks associated with the Corporation's international operations, including those related to:

- the imposition of or increase in import or export duties, surtaxes, tariffs, or customs duties;
- the imposition of import or export quotas or other trade restrictions;
- foreign tax laws and potential increased costs associated with overlapping tax structures;
- compliance with import/export laws;

- longer accounts receivable cycles in certain foreign countries, whether due to cultural, economic, or other factors;
- changes in medical reimbursement programs and regulatory requirements in international markets in which the Corporation operates; and
- economic and political instability in foreign countries, including in response to the COVID-19 pandemic and concerns over excessive levels of sovereign debt and budget deficits in countries where the Corporation markets its products that could result in an inability to pay or timely pay outstanding payables.

Modifications to the Corporation's products may require new regulatory clearances or approvals or may require the Corporation to recall or cease marketing its products until clearances or approvals are obtained. Modifications to the Corporation's products may require the submission of new regulatory filings. If a modification is implemented to address a safety concern, the Corporation may also initiate a recall or cease distribution of the affected device. In addition, if the modified devices require the submission of a new regulatory filing and the Corporation distributes such modified devices without obtaining regulatory clearances or approvals, then the Corporation may be required to recall or cease distributing the devices. Regulatory bodies can review a manufacturer's decision not to submit a modification and may disagree. Regulatory bodies can also on their own initiatives determine that clearances or approvals are required. The Corporation may make additional modifications in the future that it believes do not or will not require clearance or approval. If the Corporation begins manufacture and distribution of the modified devices and regulatory bodies later disagree the Corporation's determination and require the submission of new regulatory filing for the modifications, the Corporation may also be required to recall the distributed modified devices and to stop distribution of the modified devices, which could have an adverse effect on its business. If the regulatory bodies do not clear or approve the modified devices, the Corporation may need to redesign the devices, which could also harm its business. When a device is marketed without a required clearance or approval, the regulatory bodies have the authority to bring an enforcement action, including injunction, seizure, and criminal prosecution. Regulatory bodies consider such additional actions generally when there is a serious risk to public health or safety and the Corporation's corrective and preventive actions are inadequate to address the regulatory bodies' concerns.

If the Corporation or its suppliers fail to comply with applicable regulatory and quality management system requirements, manufacturing of its products could be negatively impacted, and sales of could suffer. The Corporation's manufacturing practices must be in compliance with regulatory bodies and quality system regulations, which govern the facility, methods, control procedures, and records of the design, manufacture, packaging, labeling, storage, shipping, installation, and servicing of its products intended for human use. The Corporation is also subject to similar state and foreign requirements and licenses, including the US FDA Quality System Regulation (QSR), the Medical Device Directive (93/42/EEC), the Medical Device Regulation (2017/745) and the ISO 13485 Quality Management System standards applicable to medical devices. In addition, the Corporation must engage in regulatory reporting in the case of potential patient safety risks and makes available its manufacturing facility, procedures, and records for periodic inspections and audits by governmental agencies. If the Corporation fails to comply with these regulations and standards, its operations could be disrupted and its manufacturing interrupted, and it may be subject to enforcement actions if its corrective actions are not adequate to ensure compliance.

The Corporation's products may in the future be subject to product recalls or voluntary market withdrawals that could harm its reputation, business, and financial results. Local and foreign governmental authorities have the authority to require the recall of commercialized products in the event of material deficiencies or defects in design or manufacture that could affect patient safety. Manufacturers may, under their own initiative, recall a product if any material deficiency in a device is found or suspected. A government-mandated recall or voluntary recall by the Corporation or one of its distributors could occur because of component failures, manufacturing errors, design, labeling defects, or other issues. Recalls, which include corrections as well as removals, of any of the Corporation's products would divert managerial and financial resources and could have an adverse effect on its financial condition, harm its reputation with customers, and reduce its ability to achieve expected revenues.

The Corporation is required to comply with medical device reporting, or Medical Devices Regulations (MDR), requirements and must report certain malfunctions, deaths, and serious injuries associated with its products, which can result in voluntary corrective actions or agency enforcement actions. Under the MDR, medical device manufacturers are required to submit information to regulatory bodies when they receive a report or become aware that a device has or may have caused or contributed to a death or serious injury or has or may have a malfunction that would likely cause or contribute to death or serious injury if the malfunction were to recur. All manufacturers placing medical devices on the market are legally bound to report any serious or potentially serious incidents involving devices they produce or sell to the competent authority in those jurisdictions the incident occurred. If this were to happen to the Corporation, the relevant competent authority would file an initial report, and there would then be a further inspection or assessment if there were issues. This would be carried out either by the competent authority or it could require that British Standard Institution (BSI), as the notified body, carry out the inspection or assessment.

Malfunctions of the Corporation's products could result in future voluntary corrective actions, such as recalls, including corrections, or customer notifications, or agency action, such as inspection or enforcement actions. If malfunctions do occur, the Corporation cannot guarantee that it will be able to correct the malfunctions adequately or prevent further malfunctions, in which case we may need to cease manufacture and distribution of the affected devices, initiate voluntary recalls, and redesign the devices; nor can we ensure that regulatory authorities will not take actions against the Corporation, such as ordering recalls, imposing fines, or seizing the affected devices. If someone is harmed by a malfunction or by product mishandling, the Corporation may be subject to product liability claims. Any corrective action, whether voluntary or involuntary, as well as defending ourselves in a lawsuit, will require the dedication of time and capital, distract management from operating the business, and may harm the Corporation's reputation and financial results.

The Corporation has a limited operating history and cannot assure you that it achieves and sustains profitability in future periods. The Corporation was incorporated in 2006 and has been profitable, on a full year basis, only in 2010. Net losses for fiscal years ended August 31, 2020 and 2019 were \$2,643,804 and \$1,951,808, respectively. To the extent that the Corporation is able to increase revenues, it expects its operating expenses will also increase as the Corporation will be expanded to meet anticipated growing demand for its products and will devote resources to its sales, marketing and research and development activities. If the Corporation is unable to reduce its operating expenses, the Corporation may not achieve profitability. Additionally, expenses will fluctuate as the Corporation makes future investments in research and development, selling and marketing and general and administrative activities, including because of new product introductions. This will cause the Corporation to experience variability in its reported earnings and losses in future periods. You should not rely on the Corporation's operating results for any prior quarterly or annual period as an indication of its future operating performance.

Dependence upon a limited number of clients. Although the Corporation has numerous clients, a relatively small number of them contribute a significant percentage of the Corporation's consolidated revenues. For the year ended August 31, 2020, revenues from two clients represented individually more than 10% of the total revenues of the Corporation, i.e. approximately 45%. The Corporation believes that the degree of dependence will diminish as its sales progress. However, if this client reduces current or expected purchases, this could have unfavourable impacts on the Corporation's activities, its revenues, its financial position, and its operating results.

Failure to innovate may adversely impact the Corporation's competitive position and may adversely impact its ability to drive price increases for its products and its product revenues. The Corporation's future success will depend upon its ability to innovate and introduce enhancements to its existing products to address the changing needs of the marketplace. The Corporation also relies on product enhancements to attempt to drive price increases for its products in its markets. Frequently, product development programs require assessments to be made of future clinical need and commercial feasibility, which are difficult to predict. Customers may forego purchases of its products and purchase its competitors' products as a result of delays in introduction of its new products and enhancements, failure to choose correctly among technical alternatives or failure to offer innovative products or enhancements at competitive prices and in a timely manner. Any delays in product releases may negatively affect the Corporation.

Delays in planned product introductions may adversely affect the Corporation and negatively impact future revenues. The Corporation may in the future experience delays in various phases of product development and commercial launch, including during research and development, manufacturing, limited release testing, marketing, and customer education efforts. Any delays in the Corporation's product launches, including in response to the COVID-19 pandemic, may significantly impede its ability to successfully compete in its markets and may reduce its revenues. The Corporation and its future collaborators may fail to develop or effectively commercialize products covered by its future collaborations if:

- the Corporation does not achieve its objectives under its collaboration agreements;
- the Corporation or its collaborators are unable to obtain patent protection for the products or proprietary technologies the Corporation develops with its collaborations; or
- the Corporation or its collaborators encounter regulatory hurdles that prevent commercialization of its products.

If the Corporation or its collaborators are unable to develop or commercialize products as planned, or if conflicts arise with its collaborators, the Corporation will be delayed or prevented from developing and commercializing products, which will harm the Corporation and financial results.

If the Corporation's facilities or systems are damaged or destroyed, it may experience delays that could negatively impact its revenues or have other adverse effects. The Corporation's facilities may be affected by natural or man-made disasters. If one of its facilities were affected by a disaster, the Corporation would be forced to rely on third-party manufacturers or to shift production to another manufacturing facility. In such an event, the Corporation would face significant delays in manufacturing which would prevent it from being able to sell its products. In addition, the Corporation's insurance may not be sufficient to cover all the potential losses and may not continue to be available to it on acceptable terms, or at all. Furthermore, although its computer and communications systems are protected through physical and software safeguards, they are still vulnerable to fire, storm, flood, power loss, earthquakes, telecommunications failures, physical or software break-ins, software viruses and similar events, and any failure of these systems to perform for any reason and for any period of time could adversely impact the Corporation's ability to operate.

The Corporation is subject to stringent domestic and foreign medical device regulation and any adverse regulatory action may materially adversely affect its financial condition and business operations. The Corporation's products, development activities and manufacturing processes are subject to extensive and rigorous regulation by numerous government agencies. To varying degrees, each of these agencies monitors and enforces the Corporation's compliance with laws and regulations governing the development, testing, manufacturing, labelling, marketing, and distribution of its medical devices. The process of obtaining marketing approval or clearance from these government agencies for new products, or for enhancements or modifications to existing products, could:

- take a significant amount of time;
- require the expenditure of substantial resources;
- involve rigorous pre-clinical and clinical testing, as well as increased post-market surveillance; and
- involve modifications, repairs or replacements of the Corporation's products, and result in limitations on the indicated uses of its products.

The Corporation cannot be certain that it will receive required approval or clearance from government agencies for new products or modifications to existing products on a timely basis. The failure to receive approval or clearance for significant new products or modifications to existing products on a timely basis could have a material adverse effect on the Corporation's financial condition and results of operations.

Foreign governmental regulations have become increasingly stringent and more common, and the Corporation may become subject to even more rigorous regulation by foreign governmental authorities in the future. Penalties for a corporation's noncompliance with foreign governmental regulation could be severe, including revocation or suspension of a corporation's business license and criminal sanctions. Any domestic or foreign governmental medical device law or regulation imposed in the future may have a material adverse effect on the Corporation's financial condition and business operations.

Physiological measurement procedures and the cardiovascular field in general are continually the subject of clinical trials conducted by the Corporation's competitors or other third parties, the results of which may be unfavorable, or perceived as unfavorable by the market, and could have a material adverse effect on the Corporation's financial condition and results of operations. Unfavorable or inconsistent clinical data from existing or future clinical trials conducted by the Corporation, by its competitors or by third parties, or the market's perception of this clinical data, may adversely impact its ability to obtain product approvals, the size of the markets in which the Corporation participates, its position in, and share of, the markets in which the Corporation participates and the Corporation's financial condition and results of operations.

Any defects or malfunctions in the computer hardware or software the Corporation utilizes in its products could cause severe performance failures in such products, which would harm its reputation and adversely affect its results of operations and financial condition. The Corporation's existing and new products depend and will depend on the continuous, effective, and reliable operation of computer hardware and software. Any defect, malfunction or other failing in the computer hardware or software utilized by the Corporation's products, including products it develops in the future, could result in inaccurate readings, misinterpretations of data, or other performance failures that could render the Corporation's products unreliable or ineffective and could lead to decreased confidence in its products, damage to its reputation, reduction in its sales and product liability claims, the occurrence of any of which could have a material adverse effect on the Corporation's results of operations and financial condition. Although the Corporation updates the computer software utilized in its products on a regular basis, there can be no guarantee that defects do not or will not in the future exist or that unforeseen malfunctions, whether within the Corporation's control or otherwise, will not occur.

Any threat to computer security could cause harm to the Corporation. The Corporation relies on secure and adequate operations of information technology systems in the conduct of its activities. Access to and the security of the information technology systems are critical to the Corporation's operations. These systems are subject to disruption, damage or failure from a variety of sources, including, but not limited to, cable cuts; damage to physical plants; natural disasters; terrorism; fire; power loss; hacking, cyber-attacks and other information security breaches; non-compliance by third party service providers; computer viruses; vandalism and theft. The Corporation's operations also depend on the timely maintenance, upgrade and replacement of networks, equipment, information technology systems and software. The systems that are in place may not be enough to guard against loss of data due to the rapidly evolving cyber threats.

The Corporation may be required to increasingly invest in better systems, software, and use of consultants to periodically review and adequately adapt and respond to dynamic cyber risks or to investigate and remediate any security vulnerabilities. Any of these and other events could result in information system failures, delays and/or increase in capital expenses. Failures in the Corporation's information technology systems could translate into operational delays, compromising, loss or disclosure of confidential, proprietary, personal, or sensitive information and third-party data, or destruction or corruption of data. Accordingly, any failure of information systems or a component of information systems could adversely impact the Corporation's reputation, business, financial condition and results of operations, as well as compliance with its contractual obligations, compliance with applicable laws, and potential litigation and regulatory enforcement proceedings. Information technology systems failures could also materially adversely affect the effectiveness of the Corporation's internal controls over financial reporting.

The Corporation does not have perfect control over its image on social media and other web applications. As a result of social media and other web-based applications, companies today are at much greater risk of losing control over how they are perceived. Damage to the Corporation's reputation can be the result of the actual or perceived occurrence of any number of events, and could include any negative publicity, whether true or not. Although the Corporation places a great emphasis on protecting its image and reputation, it does not ultimately have direct control over how it is perceived by others. Reputation loss may lead to increased challenges in developing and maintaining community relations, decreased investor confidence and act as an impediment to the Corporation's overall ability to advance its projects, thereby having a material adverse impact on the Corporation's business, financial condition or results of operations.

If the Corporation fails to obtain or maintain, or experience significant delays in obtaining, regulatory clearances or approvals for its products or product enhancements, the Corporation's ability to commercially distribute and market its products could suffer. The Corporation's products are subject to rigorous regulation by federal, provincial, state, and foreign governmental authorities. The Corporation's failure to comply with such regulations or to make adequate, timely corrections, could lead to the imposition of injunctions, suspensions or loss of marketing clearances or approvals, product recalls, manufacturing cessation, termination of distribution, product seizures, civil penalties, or some combination of such actions. The process of obtaining regulatory authorizations to market a medical device can be costly and time consuming, and there can be no assurance that such authorizations will be granted on a timely basis, if at all. If regulatory clearance or approvals are received, additional delays may occur related to manufacturing, distribution, or product labeling.

Cost containment pressures and domestic and foreign legislative or administrative reforms resulting in restrictive reimbursement practices of third-party payors or preferences for alternate therapies could decrease the demand for products purchased by the Corporation's customers, the prices which they are willing to pay for those products and the number of procedures using its devices. Physiological measurement products will be purchased principally by healthcare providers that typically bill various third-party payors, such as governmental, private insurance plans and managed care plans, for the healthcare services provided to their patients. The ability of customers to obtain appropriate reimbursement for their services and the products they provide from government and third-party payors is critical to the success of medical technology companies. The availability of reimbursement affects which products customers purchase and the prices they are willing to pay. Reimbursement varies from country to country and can significantly impact the acceptance of new technology. After the Corporation develops a promising new product, it may find limited demand for the product unless reimbursement approval is obtained from private and governmental third-party payors.

Major third-party payors for healthcare provider services continue to work to contain healthcare costs. The introduction of cost containment incentives, combined with closer scrutiny of healthcare expenditures by both private health insurers and employers, has resulted in increased discounts and contractual adjustments to healthcare provider charges for services performed and in the shifting of services between inpatient and outpatient settings. Initiatives to limit the growth of healthcare costs, including price regulation, are also underway in several countries in which the Corporation will do business. Implementation of healthcare reforms in the United States and in significant overseas markets such as Germany, Japan and other countries may limit the price or the level at which reimbursement is provided for the Corporation's products and adversely affect both its pricing flexibility and the demand for its products. Healthcare providers may respond to such cost-containment pressures by substituting lower cost products or other therapies for the Corporation's products.

Consolidation in the healthcare industry could lead to demands for price concessions or limit or eliminate the Corporation's ability to sell to certain of its significant market segments. The cost of healthcare has risen significantly over the past decade and numerous initiatives and reforms initiated by legislators, regulators and third-party payors to curb these costs have resulted in a consolidation trend in the medical device industry as well as among the Corporation's future customers, including healthcare providers. This in turn has resulted in greater pricing pressures and limitations on the Corporation's ability to sell to important market segments, as group purchasing organizations, independent delivery networks and large single accounts. The Corporation expects that market demand, government regulation, third-party reimbursement policies and societal pressures will continue to change the worldwide healthcare industry, resulting in further business consolidations and alliances which may exert further downward pressure on the prices of its products and adversely impact the Corporation's financial condition and results of operations.

The success of the OptoWire depends upon strong relationships with physicians and other healthcare professionals. If the Corporation fails to build working relationships with physicians and other healthcare professionals, many of its products may not be developed and marketed in line with the needs and expectations of the professionals who support its products. The research, development, marketing, and sales of many of its new and improved products is dependent upon the Corporation maintaining working relationships with physicians as well as other healthcare professionals, who are becoming increasingly instrumental in making purchasing decisions for its products. The Corporation relies on these professionals to provide it with considerable knowledge and experience regarding its products and the marketing and sale of its products. Physicians also assist the Corporation as researchers, marketing consultants, product consultants, inventors, and as public speakers. If the Corporation is unable to maintain its strong relationships with these professionals and continue to receive their advice and input, the development and marketing and sales of its products could suffer, which could have a material adverse effect on its financial condition and results of operations. The Corporation's relationships with physicians and other healthcare professionals and other providers that use its products are regulated under various laws. In addition, the Corporation has in place and is continuously improving its internal business integrity and compliance program and policies. Failure to comply with the United States federal antikickback law or similar state or foreign law could result in criminal or civil penalties.

The Corporation must comply with the obligations of a publicly traded corporation. As a publicly listed corporate entity, the Corporation is subject to evolving rules and regulations promulgated by a number of governmental and self-regulated organizations, including the Canadian Securities Administrators, the TSX, and the International Accounting Standards Board, which govern corporate governance and public disclosure regulations. These rules and regulations continue to evolve in scope and complexity creating many new requirements, which increase compliance costs and the risk of non-compliance. The Corporation's efforts to comply with these rules and obligations could result in increased general and administration expenses and a diversion of management time and attention from financing, development, operations and, eventually, revenue-generating activities.

5. DIVIDENDS AND DIVIDEND POLICY

As of the date of this Annual Information Form, the Corporation has not declared or paid any dividends on its issued and outstanding common shares in the last three most recently completed fiscal years. The payment of dividends in the future will be dependent on the Corporation's earnings, financial condition and such other factors as the Board of Directors considers appropriate

However, the Corporation's current policy is to reinvest future earnings to finance its growth and the development of its business. As a result, the Corporation does not intend to pay dividends in the foreseeable future.

6. GENERAL DESCRIPTION OF THE CAPITAL STRUCTURE

6.1 Common Shares

The Corporation's authorized capital consists of an unlimited number of common shares without par value. As of August 31, 2020, and as of the date of this Annual Information Form, 90,280,317 common shares were issued and outstanding as fully paid and non-assessable.

Each common share gives its holder the right to one vote and the right to receive notice of and attend all shareholders meetings of the Corporation. The common shares give their holders the right to receive, for each fiscal year of the Corporation, a dividend, when declared, in the amount and according to the terms the Board of Directors determines at its discretion. In the event of the voluntary or forced winding up of the Corporation, or a distribution of its assets for any reason whatsoever, the common shares give their holders the right to receive the remaining assets of the Corporation.

The common shares do not have any pre-emptive, conversion or redemption rights, and all have equal voting rights. There are no special rights or restrictions of any nature attached to any of the common shares, all of which rank equally as to all benefits which might accrue to the holders of the common shares.

6.2 Stock Options Issued under the Corporation's Stock Option Plan

During the fiscal year ended August 31, 2020, an aggregate number of 1,400,000 stock options were outstanding, collectively entitling the holders thereof to purchase an aggregate of up to 1,400,000 common shares as follows:

| Date of Grant | Number of Stock Options | Number of Vested Stock Options | Exercise Price | Expiry Date |
|---------------|-------------------------|--------------------------------|----------------|-------------|
| 2019-11-13 | 345,000 | - | \$0.89 | 2024-11-12 |
| 2020-01-20 | 377,500 | 180,000 | \$0.85 | 2025-01-19 |
| 2020-04-08 | 452,500 | 50,000 | \$0.55 | 2025-04-07 |
| 2020-07-14 | 65,000 | - | \$0.70 | 2025-07-13 |
| 2020-08-20 | 160,000 | - | \$0.77 | 2025-08-19 |

For further details about the stock options granted by the Corporation as of August 31, 2020, reference is made to note 15 to the Corporation’s consolidated financial statements for the last fiscal year ended August 31, 2020, which are available on SEDAR at www.sedar.com.

Between September 1st, 2020 and up to the date of this Annual Information Form, 1,400,000 stock options were granted, 100,000 stock options were exercised, 467,875 stock options expired, and 1,239,750 stock options were cancelled. As a result, and as of the date of this Annual Information Form, an aggregate number of 6,596,375 stock options issued by the Corporation were outstanding, collectively entitling the holders thereof to purchase an aggregate of up to 6,596,375 common shares.

The Board of Directors may grant stock options to employees, officers or directors of the Corporation or one of its subsidiaries and to consultants in accordance with the “*OpSens inc. 2019 Restated Stock Option Plan*” (the “Plan”), as adopted by the Board of Directors on November 13, 2019.

For the full text of the Plan, reference is made to Schedule “B” of the Corporation’s Management Proxy Circular dated December 9, 2019, prepared in connection with the annual general and special meeting of shareholders held on January 21, 2020, which is available on SEDAR at www.sedar.com.

7. **MARKET FOR SECURITIES**

7.1 **Market**

The Corporation’s common shares have been listed on the TSXV since October 17, 2006 under the trading symbol “OPS”.

On February 28, 2017, the Corporation announced final receipt of the approval of the listing of its common shares on the TSX. The common shares commenced trading on the TSX under the symbol “OPS” on March 1, 2017 at the opening of the market. The common shares were voluntarily delisted from the TSXV prior to the commencement of trading on March 1, 2017.

7.2 **Trading Price and Volume**

The following table shows the variation in price and the trading volume of the Corporation’s common shares on the TSX, monthly for each month of the fiscal year ended August 31, 2020.

| Months | High (\$) | Low (\$) | Trading Volume |
|----------------|------------------|-----------------|-----------------------|
| September 2019 | 0.95 | 0.80 | 352,949 |
| October 2019 | 0.95 | 0.82 | 234,057 |
| November 2019 | 0.91 | 0.81 | 324,795 |
| December 2019 | 0.95 | 0.74 | 1,239,434 |
| January 2020 | 0.97 | 0.79 | 748,870 |
| February 2020 | 0.88 | 0.72 | 602,597 |
| March 2020 | 0.82 | 0.39 | 868,204 |
| April 2020 | 0.66 | 0.54 | 876,250 |
| May 2020 | 0.64 | 0.59 | 392,510 |
| June 2020 | 0.79 | 0.60 | 1,080,711 |
| July 2020 | 0.80 | 0.66 | 439,762 |
| August 2020 | 0.79 | 0.61 | 1,257,730 |

8. ESCROWED SECURITIES

As of August 31, 2020, the common shares of the Corporation were neither held in escrow nor subject to a contractual restriction on transfer.

9. DIRECTORS AND OFFICERS

9.1 Name, Occupation and Securities Holding

The following table contains certain information on the Corporation's current directors and executive officers as of the date of this Annual Information Form. The directors of the Corporation are elected at the annual general meeting of shareholders for a term of office ending at the following annual general meeting or until their successor is duly elected unless their position becomes vacant earlier.

| | |
|--|---|
| <p>Alan Milinazzo Massachusetts, United States <i>Executive Chairman of the Board of the Corporation since March 2019</i> Number of common shares held: 33,498</p> | <p>Mr. Alan Milinazzo is a partner in Heidrick & Struggles' Boston office and a member of the global Healthcare and Life Sciences Practice, specializing in the medical device sector.</p> <p>Prior to joining Heidrick & Struggles, he was chief executive officer of InspireMD, a pioneer in embolic prevention systems (EPS) for coronary and vascular applications. He previously served as president and chief executive officer of Orthofix International N.V., a \$600 million publicly traded global orthopedic and spine company, and as general manager of Medtronic, Inc.'s coronary and peripheral vascular businesses, where he was instrumental in the development and commercialization of several key products including the company's first coronary drug-coated stent platform, Endeavor.</p> <p>Mr. Milinazzo also spent 12 years with Boston Scientific in multiple global sales and marketing leadership roles during a period of unprecedented top line growth in the cardiology franchise.</p> <p>Mr. Milinazzo currently serves as the executive chair of OpSens (TSX: OPS) and director and chair of the Compensation Committee of Flexion Therapeutics (Nasdaq: FLXN). Prior directorships include CasMed (Nasdaq CASM, acquired by Edwards Life Science), Nasdaq LDR Spine (Nasdaq LDRH acquired by Zimmer-Biomet), Medpace (acquired by PE sponsor Cinven), HET Systems (acquired by Covidien), LumenR (acquired by Boston Scientific), and The Musculoskeletal Transplant Foundation (MTF).</p> <p>Mr. Milinazzo earned a bachelor's degree, cum laude, from Boston College. While in college, he interned at the White House, the US House of Representatives, and the John F. Kennedy Library.</p> |
| <p>Gaétan Duplain Province of Québec, Canada <i>Director of the Corporation since October 2006</i> <i>Director of OpSens Solutions since December 2007</i> <i>President of OpSens Solutions since September 2015</i> Number of common shares held: 3,726,956</p> | <p>Mr. Gaétan Duplain is President of OpSens Solutions since September 2015. He is also a Director of the Corporation since October 2006. From October 2006 to September 2015, he was Vice-President, Oil and Gas of the Corporation. His primary responsibilities are to oversee OpSens Solutions' activities by orienting the main lines of commercial and intellectual property development, planning the work, and seeing to the implementation of the Corporation's action plan. In May 1994, he co-founded FISO Technologies Inc., a corporation specializing in the manufacturing of fiber optic sensors, for which he acted as Vice-President from July 1994 to August 2003. With this corporation, Mr. Duplain acquired experience in high-tech business development and strategic planning. He obtained a Bachelor's degree in Physical Engineering from Université Laval in May 1985 and a Master's degree in Optics and Laser from the same university in May 1986.</p> |

| | |
|---|---|
| <p>Denis M. Sirois Province of Québec, Canada <i>Director of the Corporation since January 2015</i> <i>Member of the Audit Committee, member of the Human Resources and Compensation Committee and Chairman of the Nomination Committee of the Corporation</i> Number of common shares held: 396,000</p> | <p>Mr. Denis M. Sirois is President and CEO of Telesystem Energy Ltd. since January 2017, a clean technology company which has developed the world's most efficient and reliable river hydrokinetic system producing renewable, baseload power.</p> <p>Mr. Sirois also acts as Vice President – Investments of Telesystem Ltd. since March 2006. Telesystem Ltd. is a technology focused family office with long-term value creation and innovation as core principals. Telesystem Ltd. has invested over US\$1.3B globally in venture opportunities of all stages and have concluded more than US\$22B in transactions since inception.</p> <p>Mr. Sirois has over 20 years of experience in corporate finance, mergers and acquisitions and private equity. Through the course of his career, he has been involved in transactions of all sizes, ranging from start-ups to multinational corporations. Mr. Sirois currently sits on the Board of Directors of Telesystem Ltd (and affiliates), Telesystem Energy Ltd, Northstar Earth and Space Inc., journal Le Devoir Inc. and the Corporation.</p> |
| <p>Denis Harrington Minnesota, United States <i>Director of the Corporation since January 2015</i> <i>Chairman of the Human Resources and Compensation Committee, member of the Nomination Committee and member of the Audit Committee of the Corporation</i> Number of common shares held: nil.</p> | <p>Denis Harrington is the owner of Denis L Harrington Consulting, LLC, a management and strategy consulting firm he established in December 2012 after nearly 30 years of successful leadership roles in the US Army and the Medical Device Industry. Mr. Harrington presently serves as an Executive Consultant and Board Director for several medical device companies. He has previously served as CEO for BridgePoint Medical and NexGen Medical, successfully leading BridgePoint from its development stage through commercialization and to successful acquisition by Boston Scientific in October 2012. He came to BridgePoint Medical from Boston Scientific where he spent 18 years. His last role at BSC was as Senior Vice-President of US Cardiology, Rhythm and Vascular Sales – managing over 1800 people and \$3 billion in revenue. Mr. Harrington is a graduate of the United States Military Academy at West Point.</p> |

| | |
|--|--|
| <p>Jean Lavigueur, CPA, CA Province of Québec, Canada <i>Director of the Corporation since January 2012</i> <i>Chairman of the Audit Committee of the Corporation</i></p> <p>Number of common shares held: 120,000</p> | <p>Mr. Jean Lavigueur is Chief Financial Officer of Coveo Solutions Inc., a software as a service leader in the field of enterprise search engines since April 2006. Before Coveo Solutions Inc., he co-founded and served as Chief Financial Officer of Taleo Corporation (NASDAQ:TLEO), a software as a service provider of talent management solutions, from March 1999 to May 2005, and served from June 2005 to December 2005 in other capacities, including Vice President, Finance. Prior to Taleo Corporation, Mr. Lavigueur served as Chief Financial Officer of Baan Supply Chain Solutions (“BAAN”), a software provider of enterprise resource planning (ERP), from May 1996 to February 1999, and as Chief Financial Officer of Berclain Group Inc., a supply chain management solutions vendor acquired by BAAN, from May 1991 to April 1996. Prior to his employment with Berclain Group Inc., Mr. Lavigueur worked in the audit and tax divisions of Coopers & Lybrand (now PricewaterhouseCoopers LLP), a public accounting firm. He was a member of the board of directors and of the Audit Committee of Wanted Technologies Corporation (TSXV:WAN), a software as a service vendor that provided real-time market intelligence data for the recruitment market and was the Chairman of its Special Committee of Independent Directors when the corporation was sold and privatized in November 2015. He was a member of the board of directors of iPerceptions Inc. (TSXV:IPE), a web-focused Voice of Customer analytics provider, and was Chairman of its Audit Committee and of its Special Committee of Independent Directors when the corporation was sold and privatized in March 2012. Mr. Lavigueur was also a member of the board of directors of Cossette Inc. (TSX:KOS), one of the largest advertising and communications corporation in Canada, and was the Chairman of its Audit Committee and of its Special Committee of Independent Directors when the corporation was sold and privatized in 2009. Mr. Lavigueur holds a Bachelor’s degree in Business Administration from Université Laval. He is a member of the Order of Chartered Professional Accountants of Quebec.</p> |
|--|--|

| | |
|--|--|
| <p>James Patrick Mackin Georgia, United States <i>Director of the Corporation since September 2016</i> <i>Member of the Human Resources and Compensation Committee and member of the Nomination Committee of the Corporation</i> Number of common shares held: 44,100</p> | <p>Mr. James Patrick Mackin is President and Chief Executive Officer and Chairman of CryoLife, Inc. (NYSE:CRY) (“CryoLife”) since September 2014, a leader in the manufacturing, processing, and distribution of implantable living tissues and medical devices used in cardiac and vascular surgical procedures to treat the aorta. CryoLife markets and sells products in more than 80 countries worldwide.</p> <p>Before joining CryoLife, from August 2007 to July 2014, he was President of the Cardiac Rhythm Disease Management Division, which is the largest business at Medtronic, Inc. (NYSE:MDT) (“Medtronic”). From 2004 to 2006, also at Medtronic, Inc., he held the positions of Vice President, Vascular, Western Europe where he launched the Corporation’s first drug-eluting stent called “Endeavour” and Vice President and General Manager, Endovascular Business Unit. Prior to joining Medtronic, from 1996 to 2002, Mr. Mackin worked for six years at Genzyme, Inc., serving as Senior Vice President and General Manager for the Cardiovascular Surgery Business Unit and as Director of Sales, Surgical Products division. From 1991 to 1996, Mr. Mackin spent five years at Deknatel/Snowden-Pencer, Inc. in various sales and marketing roles and three years as an Officer in the U.S. Army. Mr. Mackin received an MBA from the Kellogg School of Management at Northwestern University and is a graduate of the United States Military Academy at West Point. Mr. Mackin is also a Director for Wright Medical Group N.V. (NASDAQ:WMGI), a leading medical device company in orthopedics.</p> |
| <p>Louis Laflamme, CPA, CA Province of Québec, Canada <i>Director of the Corporation since January 2013</i> <i>President and Chief Executive Officer of the Corporation</i> <i>Director of OpSens Solutions since January 2013</i> Number of common shares held: 765,000⁽¹⁾</p> | <p>Mr. Louis Laflamme is President, Chief Executive Officer and Director of the Corporation since January 2013. His primary mandate is to see to the operational management of the Corporation. He has been Chief Financial Officer and Corporate Secretary of the Corporation from November 2005 to December 2012. From March 2005 to November 2005, he held the position of Director, Finance and Administration for DEQ Systems Corp., a corporation specialized in the manufacturing and distribution of electronic systems. From July 2002 to February 2005, Mr. Laflamme held various positions in the administrative department including the position of Vice President Finance of TGN Biotech Inc., a corporation specializing in research and development in biotechnology. From January 2002 to July 2002, Mr. Laflamme also acted as Corporate Controller at St-Raymond Forest Products Ltd, a corporation involved in the manufacturing of veneers. From October 1998 to December 2001, he was Senior Auditor in the assurance and advisory department for Samson Bélair / Deloitte & Touche (SENC). He is a member of the Ordre des comptables professionnels agréés du Québec. He holds a Bachelor’s degree in Business Administration from Université Laval obtained in May 1998.</p> |

| | |
|---|---|
| <p>Robin Villeneuve, CPA, CA Province of Québec, Canada <i>Chief Financial Officer and Corporate Secretary of the Corporation since June 2017</i></p> <p><i>Director of OpSens Solutions since June 2017</i></p> <p>Number of common shares held: 25,000</p> | <p>Mr. Robin Villeneuve is Chief Financial Officer and Corporate Secretary of the Corporation since June 2017. His principal tasks consist in defining and executing the financial strategy of the Corporation towards the shareholders and the financial community as well as in the operational activities. Mr. Villeneuve served as Chief Financial Officer for Federal Fleet Services Inc., a private maritime company. Prior to that, he worked as Chief Financial Officer for seven years at Virginia Mines Inc., a company listed on the Toronto Stock Exchange. He was part of the team that oversaw and successfully negotiated the sale of Virginia Mines to Osisko Gold Royalties Ltd. He previously held several strategic financial positions for AbitibiBowater Inc. now known as Produits Forestiers Résolu Inc. Mr. Villeneuve is also a director of Harfang Exploration Inc. (TSXV:HAR).</p> <p>Mr. Villeneuve began his career and completed his initial training with PricewaterhouseCoopers. He holds a Bachelor's degree in Business Administration from Université Laval obtained in 1992, is a member of the Order of Chartered Professional Accountants of Quebec and is also a certified corporate director.</p> |
|---|---|

Notes:

(1) Mr. Louis Laflamme personally owns 515,000 common shares, owns 84,000 common shares through 9114-6811 Québec inc., a corporation controlled by Mr. Laflamme, and holds 166,000 common shares through a registered retirement savings plan.

As of the date of this Annual Information Form, as a group, the Corporation's current directors and executive officers beneficially owned, directly or indirectly, an aggregate of 5,110,554 common shares representing 5.66% of the Corporation's outstanding common shares.

The Corporation does not have direct information on the common shares beneficially owned by the above-mentioned persons or over which they exercise control or direction. This information was provided by the directors and executive officers individually.

9.2 Cease Trade Orders, Bankruptcies, Penalties or Sanctions

To the knowledge of the Board of Directors and based on the information provided by the directors or executive officers of the Corporation, none of these persons:

- (a) is, as at the date of this Annual Information Form, or was within 10 years before this date, a director, chief executive officer or chief financial officer of any corporation, including the Corporation, that was subject to one of the following orders:
 - (i) a cease trade order, an order similar to a cease trade order or an order that denied the corporation access to any exemption under securities legislation, that was in effect for a period of more than 30 consecutive days, while the person was acting in the capacity as director, chief executive officer or chief financial officer; or
 - (ii) a cease trade order, an order similar to a cease trade order or an order that denied the corporation access to any exemption under securities legislation, that was in effect for a period of more than 30 consecutive days, and issued after the person ceased to be a director, chief executive officer or chief financial officer and which resulted from an event that occurred while the person exercised these duties.

To the knowledge of the Board of Directors and based on the information provided by the directors or executive officers of the Corporation or shareholders holding a sufficient number of securities of the Corporation to affect materially the control of the Corporation, none of these persons:

- (a) is, as at the date of this Annual Information Form or has been within the 10 years before this date, a director or executive officer of any corporation, including the Corporation, that, while the person was acting in that capacity, or within a year of that person ceasing to act in that capacity, became bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency or was subject to or instituted any proceedings, arrangement or compromise with creditors or had a receiver, receiver manager or trustee appointed to hold its assets; or
- (b) has, within the 10 years before the date of this Annual Information Form, become bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency, or become subject to or instituted any proceedings, arrangement or compromise with creditors, or had a receiver, receiver manager or trustee appointed to hold the assets of the director, executive officer or shareholder; and
- (c) has been subject to:
 - (i) any penalties or sanctions imposed by a court relating to securities legislation or by a securities regulatory authority or has entered into a settlement agreement with a security's regulatory authority; or
 - (ii) any other penalties or sanctions imposed by a court or regulatory body that would likely be considered important to a reasonable investor in making an investment decision.

Notwithstanding the above, Mr. Denis M. Sirois was a Director of CJL Capital Inc., a corporation whose securities were suspended from trading effective September 12, 2012 and transferred to NEX thereafter for failure to complete a qualifying transaction within 24 months of listing on the TSXV and which securities were suspended from trading effective May 21, 2014 for failure to file its annual consolidated financial statements for the financial period ending December 31, 2013. Effective at the close of business on September 10, 2015, CJL Capital Inc. was delisted from the NEX for failure to pay its quarterly listing maintenance fee.

10. LEGAL PROCEEDINGS AND REGULATORY ACTIONS

Since the beginning of the fiscal year ended August 31, 2020 and as of the date of this Annual Information Form, there was no legal proceedings outstanding or regulatory actions pending involving the Corporation or any of its properties or to which the Corporation is a party or to which its properties are subject, nor to the knowledge of the Corporation are any such legal proceedings contemplated or such regulatory actions threatened, as of the date hereof, which could become material to a purchaser of securities of the Corporation.

Since the beginning of the fiscal year ended August 31, 2020 and as of the date of this Annual Information Form: (i) the Corporation has not been the subject of penalties or sanctions imposed by a court relating to securities legislation or by a securities regulatory authority; (ii) the Corporation has not entered into any settlement agreement before a court relating to securities legislation or with a securities regulatory authority; and (iii) no penalties or sanctions has been imposed by a court or regulatory body against the Corporation that would likely be considered important to a reasonable investor in making an investment decision.

11. AUDIT COMMITTEE

11.1 The Audit Committee’s Charter

The Audit Committee’s charter describes the duties, responsibilities and skills required of its members as well as the terms of their nomination and dismissal and their relationship with the Board of Directors. The charter is attached to this Annual Information Form as Schedule “A”.

11.2 Composition of the Audit Committee

As of the date of this Annual Information Form, the Audit Committee is made up of the following individuals:

| Name | Independent | Financially Literate |
|---------------------------|--------------------|-----------------------------|
| Jean Lavigueur (Chairman) | Yes | Yes |
| Denis Harrington | Yes | Yes |
| Denis M. Sirois | Yes | Yes |

11.3 Relevant Education and Experience

All the members of the Audit Committee have the financial skills necessary to understand the accounting principles used by the Corporation in preparing its financial statements as well as the ability to assess the general application of such accounting principles. The Audit Committee members also have relevant experience in analyzing and evaluating financial statements that presents a level of complexity of accounting issues that can reasonably be expected to be raised by the Corporation’s financial statements, or experience actively supervising one or more individuals engaged in such activities. The members also understand the internal controls and procedures respecting the disclosure of financial information. For the relevant education and experience of the current Audit Committee members, see the table included in the “Directors and Officers” section of this Annual Information Form.

11.4 Audit Committee Oversight

During the Corporation’s fiscal year ended August 31, 2020, there was no recommendation of the Audit Committee to nominate or compensate an external auditor that was not adopted by the Board of Directors.

11.5 Reliance on Certain Exemptions

Since the beginning of the Corporation’s fiscal year ended August 31, 2020, the Corporation has not relied on the exemption provided in section 2.4, 3.2, 3.4 and 3.5 of *Regulation 52-110 respecting Audit Committees* or on any exemption granted by the securities authority under Part 8 of this regulation.

11.6 Pre-Approval Policies and Procedures

The Audit Committee has not adopted specific policies or procedures with respect to the awarding of contracts for non-audit services. However, the Audit Committee approves, from time to time, the expenses that were incurred in connection with non-audit-related services contracts.

11.7 External Auditor Service Fees

For the fiscal years ended August 31, 2019 and August 31, 2020, the following external auditor service fees were or will be invoiced to the Corporation by Deloitte LLP (“Deloitte”):

| | 2019 (\$) | 2020 (\$) |
|-----------------------------------|--------------|----------------|
| Audit Fees | 157,825 | 188,452 |
| Audit-Related Fees ⁽¹⁾ | 12,286 | 8,647 |
| Tax Fees ⁽²⁾ | 23,106 | 8,790 |
| Total | 193,217 | 205,889 |

Notes:

- (1) These fees were incurred for assurance and related services that are reasonably related to the performance of the audit or review of the financial statements and are not reported under audit fees.
- (2) These fees were incurred for government subsidy consultation & other tax consultation.

12. INTEREST OF MANAGEMENT AND OTHERS IN MATERIAL TRANSACTIONS

There are no directors, executive officers or other persons that beneficially own, or control or direct, directly or indirectly, more than 10% of any class or series of the outstanding voting securities of the Corporation, nor any associate or affiliate of such persons that have had a material interest, direct or indirect, in any transaction within the three most recently completed fiscal years or during the current fiscal year that has materially affected or is reasonably expected to materially affect the Corporation.

13. TRANSFER AGENT AND REGISTRAR

The Corporation’s transfer agent and registrar is AST Trust Company (Canada) (“AST”). The register of transfers of the Corporation’s common shares is held at AST’s offices located in its place of business at 2001 Robert-Bourassa Blvd., Suite 1600, Montréal, Québec H3A 2A6.

14. MATERIAL CONTRACTS

Except for the Distribution Agreement and the License Agreement, the Corporation did not enter into any material contract within the fiscal year ended August 31, 2020, or prior to the fiscal year ended August 31, 2020 and that is still in effect, other than contracts in the ordinary course of business.

15. INTERESTS OF EXPERTS

Deloitte act as the external auditor of the Corporation. As such, they have provided the independent auditor's report filed with the 2020 consolidated financial statements of the Corporation available on SEDAR at www.sedar.com. In connection with the audit of the Corporation's consolidated financial statements for the fiscal year ended August 31, 2020, Deloitte has confirmed to be independent within the meaning of the *Code of Ethics of Chartered Professional Accountants* (Québec).

16. ADDITIONAL INFORMATION

Additional information regarding the Corporation, including directors' and officers' remuneration and indebtedness, the principal holders of the Corporation's securities and securities authorized for issuance under equity compensation plans, if applicable, is contained in the Corporation's Management Proxy Circular dated December 9, 2019, prepared in connection with the most recent annual general and special meeting of shareholders held on January 21, 2020. Also, additional financial information is provided in the consolidated financial statements and the Management's Discussion and Analysis for the Corporation's fiscal year ended August 31, 2020.

Additional information regarding the Corporation is available on SEDAR at www.sedar.com and on the Corporation's Web site at www.OpSens.com.

SCHEDULE “A”

CHARTER OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS

I. PURPOSE

The Audit Committee is a committee of the Corporation’s Board of Directors. The primary role of the Audit Committee is to help the Board of Directors to fulfill its responsibilities with respect to financial information and controls toward the shareholders of the Corporation and the financial community. The external auditors report directly to the Audit Committee. The primary duties and responsibilities of the Audit Committee are as follows:

- to ensure the integrity of the Corporation’s financial statements, and to review all financial reports and financial information provided by the Corporation to any government authority or issued to the public as well as all other relevant document;
- to recommend the nomination of external auditors and to review and assess their efficiency, to ensure their competence and independence, and to maintain open line of communication between the external auditors, financial operations management, executive officers and the Board of Directors of the Corporation;
- to act as an objective, outside party to oversee the methods of preparing the financial information, the application of internal controls and of rules respecting business management and financial risk, and compliance with legal, ethical, and regulatory requirements;
- to encourage the continuous improvement and observance, at all levels, of the practices, methods, and policies of the Corporation.

II. COMPOSITION

The Audit Committee, including its Chairman, is made up of at least three directors of the Corporation, none of which may be Corporation employees, executive officers or “control persons” as defined hereinbelow. The Board of Directors must ensure that all members are “financially literate” as defined hereinbelow. The members of the Audit Committee are nominated by the Board of Directors, at the annual meeting of the Board of Directors following the Annual Meeting, for the next year or until their successors are nominated or elected. The Board of Directors may dismiss a member of the Audit Committee by resolution at any time, at its discretion. Unless the Chairman is nominated by the entire Board of Directors, the members of the Audit Committee may appoint the Chairman by majority vote of all members of the Audit Committee.

III. DUTIES AND RESPONSIBILITIES

1. The Audit Committee is responsible for the following:
 - a) To review the audited annual consolidated financial statements and to recommend them to the Board of Directors for approval.
 - b) To review with the Corporation’s financial operations management and external auditors the financial statements, management’s discussion & analysis and any other documents

relating to the financial results before they are filed with regulatory agencies and reported.

- c) To review any document that contains the audited annual consolidated financial statements or includes them by reference, such as prospectuses, press releases announcing financial results and interim results before they are reported.
- d) To amend or add to the Corporation's security policies from time to time. The Audit Committee reports to the Board of Directors annually on the relevance of the instructions in effect for management of the Corporation's security programs.

2. In fulfilling its mandate, the Audit Committee is required:

- a) To see to the implementation of internal control measures and processes enabling the Chief Executive Officer and Chief Financial Officer to certify the financial statements and any other information document required under securities legislation.
- b) To recommend external auditors to the Board of Directors, to evaluate their independence and effectiveness, and to approve the audit fees and any other remuneration paid to the external auditors.
- c) To oversee relations between management and the external auditors, including the review of any letter of recommendation or any other external auditor's report, to discuss any significant difference of opinion or disagreement between management and the external auditors and to see that they are resolved.
- d) To review annually all significant relations between the Corporation and the external auditors to evaluate the external auditors' independence and discuss this with them, and to report to the Board of Directors.
- e) To review the performance of the external auditors and to approve any proposal for replacement when circumstances so warrant. To examine, with management, the reasons for retaining the services of other firms.
- f) To meet periodically with the external auditors, without management in attendance, to discuss the main risks, internal controls and any approach undertaken by management to control these risks, and to discuss the accuracy and completeness of the financial statements. Specific attention should be paid to the capability of internal controls to detect any payment, transaction or method that may be deemed illegal or otherwise inappropriate.
- g) To see to the availability of the external auditors in accordance with the needs of the Audit Committee and the Board of Directors. To ensure that the external auditors report directly to the Audit Committee and that they answer to the Board of Directors and the Audit Committee as auditor representatives towards whom the auditors are ultimately responsible.
- h) To oversee the work of the external auditors retained for the preparation and issuance of an auditor's report or for other audit, review, or certification services.

- i) To review and approve the policies regarding the hiring of employees or former employees of external auditors, past or present.
- j) To review the external audit program and fees.
- k) To review the external auditor's report on the audited annual financial statements.
- l) To review the problems identified during the audit and, if applicable, the limitations and restrictions imposed by management or any significant accounting issue for which management requests a second opinion.
- m) To review the observations, both positive and negative, made by the external auditors during their audit.
- n) To review with management and the external auditors the Corporation's main accounting policies, the impact of other applicable accounting policies, and the forecasts and decisions of management that may have a significant impact on the financial results.
- o) To review new accounting issues and their potential impact on the financial information of the Corporation.
- p) To review and approve any request for consultation with external auditors and to be informed of any request from management for non-audit services and the fees related thereto.
- q) To review with management, the external auditors and legal counsel any legal proceedings or claim, including tax assessments, that could have a significant impact on the Corporation's financial position and financial performance, and to ensure that they are disclosed in an appropriate manner.
- r) To review the conclusions of the external auditor's evaluation of the internal control system as well as management's response.
- s) To review with management the manner of ensuring and verifying the security of the Corporation's assets (including intellectual property) and information systems, the competence of the personnel holding key positions, and improvement projects.
- t) To review management's code of conduct and compliance with corporate governance policies.
- u) To review annually the legal requirements, the requirements of regulatory authorities, and the impact of any breach of these requirements on the financial information reported and on the Corporation's reputation.
- v) To receive periodic reports on the nature and scope of compliance with security policies. The Board of Directors must be informed of any non-compliance having significant consequences, and of the corrective measures and schedule proposed for remedying it.

- w) To review with management the accuracy and timeliness of the filings with regulatory authorities.
- x) To review the Corporation's business plans periodically.
- y) To review the annual audit program of the Corporation's external auditors.
- z) To review annually the Corporation's general insurance coverage to ensure sufficient protection of the Corporation's assets, including without limitation, directors and officers' liability insurance and coverage of key personnel.
- aa) To carry out any other task required by the Corporation's articles and any relevant securities policy or regulation.
- bb) To implement methods to:
 - (i) receive and analyze complaints addressed to the Corporation in respect of audit, internal control, or accounting matters; and
 - (ii) receive any confidential and anonymous observation from Corporation employees with respect to audit or accounting issues subject to security.
- 3. The Audit Committee may retain the services of external legal counsel or other counsel, communicate directly and independently with them, and pay their fees.
- 4. The Audit Committee reviews the Charter of the Audit Committee annually and recommends any amendment it deems appropriate to the Board of Directors.

IV. SECRETARY

The Secretary of the Audit Committee is nominated by the Chairman.

V. MEETINGS

- 1. The Audit Committee meets on the dates, at the times and in the places determined by the Audit Committee, at least four times a year. The Audit Committee meets with management and the external auditors separately at least once a year.
- 2. The members may meet in person, by telephone or by videoconference.
- 3. A written resolution signed by all members of the Audit Committee has the same value as one adopted at a meeting of the Audit Committee.
- 4. Meetings of the Audit Committee will be held from time to time, as decided by the Audit Committee or the Audit Committee Chairman, upon 48 hours' notice to all Audit Committee members. A quorum of Audit Committee members may waive the notice period.
- 5. A meeting of the Audit Committee may be called by any member of the Audit Committee or by the external auditors. The external auditors receive notice of all meetings of the Audit Committee.

6. The minutes of each Audit Committee meeting are tabled at the first meeting of the Board of Directors following such Audit Committee meeting.

VI. QUORUM

A majority of members constitutes quorum at any Audit Committee meeting.

VII. DEFINITIONS

Under *Regulation 52-110 respecting Audit Committees*:

“Financially literate individual” means “an individual who has the ability to read and understand a set of financial statements that present a breadth and level of complexity of accounting issues that are generally comparable to the breadth and complexity of the issues that can reasonably be expected to be raised by the Corporation’s financial statements.”

“Control person” means “any person who holds, or is part of a group of persons who hold, a sufficient number of Corporation securities to enable him to exercise significant control over the Corporation or more than 20% of the Corporation’s outstanding voting shares, unless it is obvious that the holder of these securities cannot exercise significant control over the Corporation.”